



(86) Date de dépôt PCT/PCT Filing Date: 2000/03/08
(87) Date publication PCT/PCT Publication Date: 2000/09/14
(45) Date de délivrance/Issue Date: 2009/12/08
(85) Entrée phase nationale/National Entry: 2001/09/05
(86) N° demande PCT/PCT Application No.: US 2000/005915
(87) N° publication PCT/PCT Publication No.: 2000/053771
(30) Priorité/Priority: 1999/03/08 (US60/123,267)

(51) Cl.Int./Int.Cl. *C12N 15/53* (2006.01),
A01H 5/00 (2006.01), *A01H 5/10* (2006.01),
A23L 1/00 (2006.01), *C12N 15/11* (2006.01),
C12N 15/82 (2006.01), *C12N 5/10* (2006.01),
C12N 9/02 (2006.01)


(72) Inventeurs/Inventors:
STEELE, CHRISTOPHER L., US;
DIXON, RICHARD A., US

(73) Propriétaire/Owner:
THE SAMUEL ROBERTS NOBLE FOUNDATION, INC.,
US

(74) Agent: KIRBY EADES GALE BAKER

(54) Titre : MANIPULATION GENETIQUE D'ISOFLAVONOIDES

(54) Title: GENETIC MANIPULATION OF ISOFLAVONOIDS



(57) Abrégé/Abstract:

Soybean and *Medicago truncatula* CYP93C genes have been isolated which encode a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone. Plants can now be genetically engineered to produce isoflavones that provide potential human health benefits and increase disease resistance in plants. Isoflavones can now be produced in transgenic plants species in which isoflavones do not naturally occur, i.e., in species other than legumes. Alternatively, introducing infection-inducible isoflavonoid biosynthesis into non-legumes qualitatively complements these plants' phytoalexin defenses against microbial pathogens, whereas over-expression of the isoflavonoid pathway in legumes quantitatively increases this defense response. Finally, modifying the extent of production of isoflavonoids in legume roots positively impacts nodulation efficiency and therefore plant yield.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/53, 15/82, 15/11, 9/02, 5/10, A01H 5/00, 5/10, A23L 1/00	A1	(11) International Publication Number: WO 00/53771 (43) International Publication Date: 14 September 2000 (14.09.00)
--	-----------	--

(21) International Application Number: PCT/US00/05915

(22) International Filing Date: 8 March 2000 (08.03.00)

(30) Priority Data:
60/123,267 8 March 1999 (08.03.99) US

(71) Applicant (for all designated States except US): THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. [US/US]; 2510 Sam Noble Parkway, Ardmore, OK 73401 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): STEELE, Christopher, L. [US/US]; 617 Campbell, Ardmore, OK 73401 (US). DIXON, Richard, A. [GB/US]; 206 Woods Lane, Ardmore, OK 73401 (US).

(74) Agents: HANSEN, Eugenia, S. et al.; Sidley & Austin, Suite 3400, 717 N. Harwood, Dallas, TX 75201-6570 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: GENETIC MANIPULATION OF ISOFLAVONOIDS



(57) Abstract

Soybean and *Medicago truncatula* CYP93C genes have been isolated which encode a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone. Plants can now be genetically engineered to produce isoflavones that provide potential human health benefits and increase disease resistance in plants. Isoflavones can now be produced in transgenic plants species in which isoflavones do not naturally occur, i.e., in species other than legumes. Alternatively, introducing infection-inducible isoflavonoid biosynthesis into non-legumes qualitatively complements these plants' phytoalexin defenses against microbial pathogens, whereas over-expression of the isoflavonoid pathway in legumes quantitatively increases this defense response. Finally, modifying the extend of production of isoflavonoids in legume roots positively impacts nodulation efficiency and therefore plant yield.

GENETIC MANIPULATION OF ISOFLAVONOIDS

TECHNICAL FIELD OF THE INVENTION

The invention relates to gene manipulation in plants.

BACKGROUND OF THE INVENTION

5 The flavonoids are a major class of phenylpropanoid-derived plant natural products. Their fifteen carbon (C₆-C₃-C₆) backbone can be arranged as a 1,3-diphenylpropane skeleton (flavonoid nucleus) or as a 1,2-diphenylpropane skeleton (isoflavonoid nucleus). Although 1,3-diphenylpropane flavonoid derivatives are almost ubiquitous among terrestrial plants, the 1,2-diphenylpropane isoflavonoids are
10 restricted primarily to the Leguminosae, although they occur rarely in other families such as the Apocynaceae, Pinaceae, Compositae, and Moraceae (Tahara, S. and R. K. Ibrahim, 1995, "Prenylated isoflavonoids - an update," *Phytochemistry* 38: 1073-1094).

 The limited taxonomic distribution of the isoflavonoids is directly related to
15 the occurrence of the enzyme complex isoflavone synthase (IFS), which catalyzes the aryl migration reaction leading to the formation of an isoflavone from a flavanone. While flavanones are ubiquitous in higher plants, the IFS reaction, which is a two-step process specific for isoflavonoid biosynthesis (Kochs, G. and H. Grisebach, 1986, "Enzymic synthesis of isoflavones," *European J Biochem* 155: 311-318), is limited to
20 the Leguminosae and the other diverse taxa in which isoflavonoids are occasionally found.

 The presence of isoflavonoids provides several advantages to plants. One such advantage is provided by the function of isoflavonoids as antimicrobial phytoalexins in plant-microbe interactions. For example, the simple isoflavones daidzein and
25 genistein act as initial precursors in the biosynthesis of various antimicrobial isoflavonoid phytoalexins in a wide variety of legumes (Dixon, R. A. and N. L. Paiva, 1995, "Stress-induced phenylpropanoid metabolism," *Plant Cell* 7: 1085-1097). Isoflavonoid compounds have been shown to accumulate in infected plant cells to

levels known to be antimicrobial *in vitro*. The temporal, spatial and quantitative aspects of accumulation are consistent with a role for these compounds in disease resistance (Rahe, J. E., 1973, "Occurrence and levels of the phytoalexin phaseollin in relation to delimitation at sites of infection of *Phaseolus vulgaris* by *Colletotrichum lindemuthianum*," *Canadian J Botany* 51: 2423-2430; Hadwiger, L. A. and D. M. Webster, 1984, "Phytoalexin production in five cultivars of pea differentially resistant to three races of *Pseudomonas syringae* pv. *pisi*," *Phytopathology* 74: 1312-1314; Long, et al., 1985, "Further studies on the relationship between glyceollin accumulation and the resistance of soybean leaves to *Pseudomonas syringae* pv. *glycinea*," *Phytopathology* 75: 235-239; Bhattacharyya, M. K. and E. W. B. Ward, 1987, "Biosynthesis and metabolism of glyceollin I in soybean hypocotyls following wounding or inoculation with *Phytophthora megasperma* f. sp. *glycinea*," *Physiol and Mol Plant Pathology* 31: 387-405). Moreover, it has been reported that many plant pathogens are much more sensitive to phytoalexins of non-host species than they are to the phytoalexins of their natural hosts, because they can often detoxify the host's phytoalexins. (VanEtten, et al., 1989, "Phytoalexin detoxification: importance for pathogenicity and practical implications," *An Rev Phytopathology* 27: 143-164).

Isoflavonoids also function in plant-microbe interactions in the establishment of bacterial or fungal symbioses with plants. Isoflavonoids have been reported to regulate bacterial nodulation genes, acting as a major *nod* gene inducer (Kosslak, et al., 1987, "Induction of *Bradyrhizobium japonicum* common *nod* genes by isoflavones isolated from *Glycine max*," *Proc Natl Acad Sci USA* 84: 7428-7432) and/or transcription activator (Dakora, et al., 1993, "Common bean root exudates contain elevated levels of daidzein and coumestrol in response to *Rhizobium* inoculation," *Mol Plant-Microbe Interact* 6: 665-668). Isoflavonoids have also been shown to have a role on the establishment of the symbiotic vesicular arbuscular mycorrhizal (VAM) association of the fungus *Glomus* with legume roots. (Kape, et al., 1992, "Legume root metabolites and VA-mycorrhiza development," *J Plant Physiol* 141: 54-60). Xie et al have reported that the isoflavonoids coumestrol, daidzein and genistein have small but significant stimulatory effects on the degree of mycorrhizal colonization of soybean, and that one effect of isoflavonoids on the

soybean mycorrhizal symbiosis could be via induction of nodulation factors from co-colonizing Rhizobia, since nod-factors have also been shown to stimulate fungal colonization (Xie, et al., 1995, "Rhizobial nodulation factors stimulate mycorrhizal colonization of nodulating and nonnodulating soybeans," *Plant Physiology* 108: 1519-1525).

In addition to the advantages that the presence of isoflavonoids confers to plants, a significant body of evidence indicates that dietary consumption of isoflavonoids can provide benefits to human health. Dietary isoflavones have been ascribed strong cancer chemopreventative activity in humans, and display a range of pharmacological activities suggestive of various other health promoting effects, including phytoestrogen activity as both estrogenic and anti-estrogenic agents (Coward, et al., 1993, "Genistein, daidzein, and their -glycoside conjugates: antitumor isoflavones in soybean foods from American and Asian diets," *J Agricultural and Food Chemistry* 41: 1961-1967; Martin, et al., 1996, "Interactions between phytoestrogens and human sex steroid binding protein," *Life Sciences* 58: 429-436); anticancer effects associated with phytoestrogenic activity (Lee, et al., 1991, "Dietary effects on breast-cancer risk in Singapore," *Lancet* 337: 1197-1200; Adlercreutz, et al., 1991, "Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet," *Am J Clin Nutr* 54: 1093-1100); anticancer effects associated with inhibition of several enzymes including DNA topoisomerase and tyrosine protein kinase (Akiyama, et al., 1987, "Genistein, a specific inhibitor of tyrosine-specific protein kinases," *J Biol Chem* 262: 5592-5599; Uckun, et al., 1995, "Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases," *Science* 267: 886-891); suppression of alcohol consumption (Keung, W. M. and B. L. Vallee, 1993, "Daidzin: A potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase," *Proc Natl Acad Sci USA* 90: 1247-1251; Keung, et al., 1995, "Daidzin suppresses ethanol consumption by Syrian golden hamsters without blocking acetaldehyde metabolism," *Proc Natl Acad Sci USA* 92: 8990-8993); antioxidant activity (Arora, et al., 1998, "Antioxidant activities of isoflavones and their biological metabolites in a liposomal system," *Arch Biochem Biophys* 356: 133-141; Tikkanen, et

al., 1998, "Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance," *Proc Natl Acad Sci USA* 95: 3106-3110); effects on calcium metabolism, some of which may be linked to protective effects against osteoporosis (Tomonaga, et al., 1992, "Isoflavonoids, genistein, PSI-tectorigenin, and orobol, increase cytoplasmic free calcium in isolated rat hepatocytes," *Biochem Biophys Res Com* 182: 894-899; Draper, et al., 1997, "Phytoestrogens reduce bone loss and bone resorption in oophorectomized rats," *J Nutr* 127: 1795-1799); and cardiovascular effects (Wagner, et al., 1997, "Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys," *Metabolism - Clinical and Experimental* 46: 698-705).

At present, the only dietary sources of isoflavonoids for humans are certain legumes such as soybean or chickpea. The development of methods to genetically manipulate isoflavonoids in plants, either to widen the source of dietary isoflavonoids for humans, or to exploit the biological activities of isoflavonoids for plant protection and improvement, is wholly dependent on the availability of cloned genes encoding the various enzymes of isoflavonoid biosynthesis. Of these, the isoflavone synthase (IFS) complex constitutes the first committed reactions, and as such represents the means to introduce isoflavonoids into plants that do not possess the pathway.

In 1984, Hagmann and Grisebach provided the first evidence for the enzymatic conversion of flavanone to isoflavone (the IFS reaction) in a cell free system (Hagmann, M. and H. Grisebach, 1984, "Enzymatic rearrangement of flavanone to isoflavone," *FEBS Letters* 175: 199-202). They demonstrated that microsomes from elicitor-treated soybean cell suspension cultures could catalyze the conversion of 2(S)-naringenin to genistein, or of 2(S)-liquiritigenin to daidzein, in the presence of NADPH. The crude microsomal enzyme preparation, which was stable at -70°C but had a half-life of only 10 minutes at room temperature, was absolutely dependent on NADPH and molecular oxygen. It was subsequently shown that the reaction proceeded in two steps. The flavanone was converted in a cytochrome P450-catalyzed reaction requiring NADPH and O₂ to the corresponding 2-hydroxyisoflavanone. This

relatively unstable compound, which could, however, be identified by mass spectrometric analysis, then underwent dehydration to yield the isoflavone. The dehydration reaction appeared to be catalyzed by an enzyme present predominantly in the cytoplasmic supernatant, although it was not possible to remove all this activity
5 from the microsomes. The corresponding 2-hydroxyisoflavanone spontaneously converted to genistein, for example, in methanol at room temperature. Kinetic analysis indicated that the 2-hydroxyisoflavanone was formed prior to genistein, consistent with its being an intermediate in isoflavone formation. (Kochs, G. and H. Grisebach, 1986, "Enzymic synthesis of isoflavones," *European J Biochem* 155: 311-
10 318).

Involvement of cytochrome P450 in the 2-hydroxyisoflavanone synthase reaction was confirmed by inhibition by CO, replacing O₂ with N₂, and examining the effects of a range of known P450 inhibitors of which ancymidol was the most effective. The enzyme co-migrated with the endoplasmic reticulum markers
15 cinnamate 4-hydroxylase (another cytochrome P450) and cytochrome b5 reductase on Percoll gradients. The enzyme is stereoselective, and (2*R*)-naringenin is not a substrate. (Kochs, G. and H. Grisebach, 1986, "Enzymic synthesis of isoflavones," *European J Biochem* 155: 311-318).

The origin of the 2-hydroxyl group was determined from studies on the IFS
20 present in microsomes from elicited cell cultures of *Pueraria lobata*. ¹⁸O from ¹⁸O₂ was incorporated into the 2-hydroxyl group, resulting in a 2-hydroxyisoflavanone with molecular ion shifted by two mass units, whereas there was no corresponding shift in the molecular ion of daidzein, consistent with the subsequent dehydration reaction (Hashim, et al., 1990, "Reaction mechanism of oxidative rearrangement of flavanone
25 in isoflavone biosynthesis," *FEBS Letters* 271: 219-222). The currently accepted model for the reaction pathway of IFS as illustrated in Fig. 1, therefore, involves P450-catalyzed hydroxylation coupled to aryl migration, a reaction with mechanistic similarities to the well described proton migration mechanism of some P450 reactions (Hakamatsuka, et al., 1991, "P-450-dependent oxidative rearrangement in isoflavone

biosynthesis: reconstitution of P-450 and NADPH:P450 reductase," *Tetrahedron* 47: 5969-5978).

Currently, there have been no reports on purification to homogeneity or molecular cloning of the cytochrome P450 of the IFS complex because of the extreme lability of the enzyme. The 2-hydroxyisoflavanone synthase cytochrome P450 from *Pueraria* has been solubilized with TritonTM X-100, and partially purified by DEAE-SepharoseTM chromatography; the enzymatic reaction could be reconstituted by addition of NADPH cytochrome P450 reductase that separated from the hydroxylase on the ion exchange column (Hakamatsuka, et al., 1991, *Tetrahedron* 47: 5969-5978). A 2-hydroxyisoflavanone dehydratase has been purified from elicitor-treated *P. lobata* cells, and has been shown to be a soluble monomeric enzyme of subunit Mr 38,000 (Hakamatsuka, et al., 1998, "Purification of 2-hydroxyisoflavanone dehydratase from the cell cultures of *Pueraria lobata*," *Phytochemistry* 49: 497-505). It is not yet clear whether this enzyme physically associates with the P450 hydroxylase catalyzing the aryl migration, or even whether this activity is essential for isoflavone formation *in planta* in view of the spontaneous conversion of 2-hydroxyisoflavanone to isoflavone.

Flavanone is a potential substrate for more than one type of hydroxylation reaction at the 2-position. Thus, elicitor-treated cell cultures of alfalfa and *Glycyrrhiza echinata* have been shown to accumulate the dibenzoylmethane licodione (Kirikae, et al., 1993, "Biosynthesis of a dibenzoylmethane, licodione, in cultured alfalfa cells induced by yeast extract," *Biosci Biotech Biochem* 57: 1353-1354). Licodione synthase is, by classical criteria, a cytochrome P450, the activity of which is induced by yeast elicitor in *Glycyrrhiza* cells (Otani, et al., 1994, "Licodione synthase, a cytochrome P450 monooxygenase catalyzing 2-hydroxylation of 5-deoxyflavanone, in cultured *Glycyrrhiza echinata* L. cells," *Plant Physiol* 105: 1427-1432). The reaction it catalyzes involves 2-hydroxylation of flavanone followed by hemiacetal opening instead of aryl migration, and the reaction was thought to have mechanistic similarities to the flavone synthase II enzyme previously characterized from soybean (Kochs, G. and H. Grisebach, 1987, "Induction and characterization of a NADPH-dependent flavone synthase from cell cultures of soybean," *Z. Naturforsch* 42C: 343-

348). A gene encoding the flavone synthase II/licodione synthase from *Glycyrrhiza* has been cloned (Akashi, et al., 1998, "Identification of a cytochrome P450 cDNA encoding (2S)-flavanone 2-hydroxylase of licorice (*Glycyrrhiza echinata* L.: *Fabaceae*) which represents licodione synthase and flavone synthase II, "FEBS Letters 431: 287-290), and a different cytochrome P450 gene encoding flavone synthase II has recently been cloned from *Gerbera hybrida* (Martens, S. and G. Forkmann, "Cloning and expression of flavone synthase II from *Gerbera* hybrids," *Plant J* 20: 611-618).

10 Although the reactions catalyzed by IFS are critical for the formation of all isoflavonoids in plants, there have been no previous reports of the isolation of genes encoding components of isoflavone synthase, although genes encoding most of the other enzymes of the isoflavonoid pathway, including downstream enzymes converting simple isoflavones to antimicrobial phytoalexins, have been characterized
15 (Dixon, et al., 1995, "The isoflavonoid phytoalexin pathway: from enzymes to genes to transcription factors," *Physiologia Plantarum* 93: 385-392). Thus, the unavailability of isoflavone synthase genes has made it heretofore impossible to utilize the downstream genes for regulating isoflavonoid concentrations in legumes and other plants that do have the isoflavonoid pathway, or for engineering
20 antimicrobial and pharmacologically active isoflavonoids in transgenic plants of species that do not have the isoflavonoid pathway.

Genes encoding the enzyme catalyzing the first step of the isoflavone synthase reaction have now been isolated and purified from soybean and *Medicago truncatula*
25 (barrel medic).

Certain exemplary embodiments of the invention can provide for a method for introducing into a naturally non-isoflavonoid-producing plant species an enzyme catalyzing the aryl migration of a flavanone to form an isoflavanone intermediate or

an isoflavone, said enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, the method comprising: introducing a DNA segment encoding said enzyme into said plant to form a transgenic plant, wherein said transgenic plant expresses said DNA segment under the control of a suitable constitutive or inducible promoter when
5 said transgenic plant is exposed to conditions which permit expression.

Certain exemplary embodiments of the invention can further provide for a method for increasing the level of isoflavonoid compounds in naturally isoflavonoid-producing plants comprising: introducing a DNA segment encoding an enzyme
10 catalyzing the aryl migration of a flavanone to yield an isoflavonoid to form a transgenic plant, said enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, wherein said transgenic plant expresses said DNA segment under the control of a suitable constitutive or inducible promoter when said transgenic plant is exposed to conditions which permit expression.

15

Certain exemplary embodiments of the invention can further provide for a method for synthesizing an isoflavanone intermediate or an isoflavone from a flavanone by expressing a recombinant CYP93C gene segment encoding an enzyme having an amino acid sequence as set forth in SEQ ID NO:2, in a suitable bacterial,
20 fungal, algal, or insect cell system.

Certain exemplary embodiments of the invention can further provide for a method of reducing the levels of isoflavonoid compounds in a naturally isoflavonoid-producing plant comprising introducing and expressing an antisense or gene silencing
25 construct that contains a CYP93C gene encoding an enzyme having an amino acid sequence as set forth in SEQ ID NO:2, into said plant.

Certain exemplary embodiments of the invention can further provide for a naturally non-isoflavonoid producing plant cell transformed by introducing a DNA
30 segment encoding an enzyme catalyzing the aryl migration of a flavanone to form an

isoflavanone intermediate or an isoflavone, said enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, wherein said transgenic plant cell expresses said DNA segment under the control of a suitable constitutive or inducible promoter when exposed to conditions which permit expression.

5

Certain exemplary embodiments of the invention can further provide for a naturally isoflavonoid-producing plant cell transformed by introducing a DNA segment encoding an enzyme catalyzing the aryl migration of a flavanone to yield an isoflavonoid to form a transformed plant cell, said enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, wherein said transformed plant cell expresses said DNA segment under the control of a suitable constitutive or inducible promoter when exposed to conditions which permit expression.

Certain exemplary embodiments of the invention can further provide for a transgenic plant cell having reduced levels of isoflavonoid compounds, said plant cell transformed by introducing an antisense or gene silencing construct that contains a CYP93C gene encoding an enzyme having an amino acid sequence as set forth in SEQ ID NO:2, into said plant cell.

Certain exemplary embodiments of the invention can further provide for an isolated gene or DNA segment comprising a portion which encodes a cytochrome P450 of the CYP93 family that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein said portion consists of nucleotide 36 to nucleotide 1598 of the sequence depicted in SEQ ID NO:1.

25

Certain exemplary embodiments of the invention can further provide for a protein encoded by a portion of an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an

isoflavanone intermediate or an isoflavone, wherein said portion consists of nucleotide 36 to nucleotide 1598 of the sequence depicted in SEQ ID NO:1.

5 Certain exemplary embodiments of the invention can further provide for a transgenic plant cell transformed with an isolated gene or DNA segment which encodes a cytochrome P450 enzyme that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, said enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, wherein said transgenic plant cell exhibits increased levels of an isoflavonoid when compared to
10 the level of said isoflavonoid in plant cells of the same species which do not comprise said isolated gene or DNA segment.

Certain exemplary embodiments of the invention can further provide for a method of transforming a plant with an isolated gene or DNA segment which encodes
15 a cytochrome P450 enzyme that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, said enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, wherein said transgenic plant exhibits increased levels of an isoflavonoid when compared to the level of said isoflavonoid in plants of the same species which do not comprise said isolated gene or
20 DNA segment.

Certain exemplary embodiments of the invention can further provide for a transgenic plant cell comprising at least one recombinant DNA sequence encoding a cytochrome P450 enzyme that can catalyze the aryl migration of a flavanone to yield
25 an isoflavanone intermediate or an isoflavone, said enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, wherein said transgenic plant cell exhibits an increased level of an isoflavonoid when compared to the level of said isoflavonoid in plant cells of the same species which do not comprise said recombinant DNA sequence.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 depicts the currently accepted model for the reaction pathway of IFS wherein the flavanone is converted in a cytochrome P450-catalyzed reaction requiring NADPH and O₂ to the corresponding 2-hydroxyisoflavanone which then undergoes
5 dehydration to yield the isoflavone.

Fig. 2 depicts the nucleotide sequence of soybean CYP93C1v2.

Fig. 3 depicts the amino acid sequence of soybean CYP93C1v2 compared to licorice CYP93B1.

Fig. 4 depicts the nucleotide sequence of *Medicago truncatula* mtIFSE3.

Fig. 5 depicts the amino acid sequence of *Medicago truncatula* mtIFSE3
5 compared to soybean CYP93C1v2.

Fig. 6A and Fig. 6B depict HPLC traces of extracts from pooled tissues (leaves, shoots, flowers) of *Arabidopsis thaliana* ecotype Columbia harboring an empty tDNA vector (Fig. 6A) and *Arabidopsis thaliana* ecotype Columbia harboring the soybean CYP93C1v2 cDNA sequence (Fig. 6B). The empty vector transformed
10 line contains a number of flavonol glycosides and other phenolic compounds that are also present in the CYP93C1v2 transformed line. These compounds were identified as (a) rhamnose (Rha)- glucose (Glc)- quercetin (Q), (b) uncharacterized conjugate of Q, (c) Rha-Glc-Rha-Kaempferol (K), (d) Glu-Rha-Q, (e) Rha-Rha-Q, (f) Glc-Rha-K, (g) sinapic acid, (h) Rha-Rha-K. Three additional compounds were observed in the
15 CYP93C1v2 transformed line (Fig. 6B), and labeled "1," "2" and "3." Fig. 6C depicts a total ion chromatogram of partially purified peaks 2 and 3, and the insets show the specific ions generated from these compounds. Peak 2 has a parental molecular mass ion of 579.5 consistent with genistein conjugated to a glucose-rhamnose disaccharide, and two further mass ions of 417.5 and 271.3, representing Rha-genistein and free
20 genistein, respectively. Peak 3, which has a parental molecular ion of mass 417.5, is thereby identified as Rha-genistein.

Fig. 7A and Fig. 7B depict HPLC traces of the same extracts as shown in Fig. 6A (empty-vector transformed) and Fig. 6B, (CYP93C1v2 transformed), but following digestion with β -glucosidase. Peaks 2 and 3 remained at the same retention time as in
25 Fig. 6A and 6B. However, Peak 1 disappeared, and was replaced with a new Peak 4 of much later retention time. Fig. 7C shows the total ion chromatograph of purified Peak 4, and the inset shows the parental molecular ion, with mass of 271.2, consistent with Peak 4 being free genistein. Fig. 7D shows a total ion chromatograph, and the parental molecular ion, of an authentic sample of genistein.

Fig. 8A , 8B, 8C and 8D are high performance liquid chromatography (HPLC) chromatograms depicting the presence of new peaks at RT 29.96 and 37.7 min representing the presence of the isoflavone daidzein formed from the flavanone liquiritigenin, or the isoflavone genistein formed from the flavanone naringenin, in insect cell microsomes expressing CYP93C1v2. Fig. 8A depicts the presence of NADPH during incubation with liquiritigenin. Fig. 8B depicts the absence of NADPH during incubation with liquiritigenin. Fig. 8C depicts the presence of NADPH during incubation with naringenin. Fig. 8D depicts the lack of a reaction when soybean CYP93E expressed in insect cells is incubated with liquiritigenin in the presence of NADPH.

Fig. 9A and Fig. 9B are mass spectra of BSTFA (*N,O*-bis(trimethylsilyl) trifluoroacetamide) derivatives. Fig. 9A depicts the mass spectrum of the BSTFA derivative of the product of the reaction catalyzed by CYP93C1v2 in insect cells using liquiritigenin as substrate, and Fig. 9B shows the mass spectrum of the BSTFA derivative of an authentic sample of daidzein .

SUMMARY OF THE INVENTION

In one aspect, the invention is a method for introducing into a naturally non-isoflavonoid-producing plant species the enzyme catalyzing the aryl migration of a flavanone to form an isoflavanone intermediate or an isoflavone, comprising introducing a DNA segment encoding the enzyme into the plant to form a transgenic plant, wherein the transgenic plant expresses the DNA segment under the control of a suitable constitutive or inducible promoter when the transgenic plant is exposed to conditions which permit expression. The DNA segment can comprise isolated genomic DNA or recombinant DNA. Preferably, the DNA segment is a CYP93C gene. An exemplary DNA segment from a soybean CYP93C gene consists essentially of the sequence from about nucleotide 36 to about nucleotide 1598 of the sequence depicted in SEQ ID NO:1. Another preferred DNA segment comprises a *Medicago truncatula* homolog of a CYP93C gene, more preferably, the sequence from about nucleotide 92 to about nucleotide 1657 of the sequence depicted in SEQ ID NO:4. Plants transformed by this method may also preferably express chalcone synthase,

chalcone reductase, and chalcone isomerase genes to cause in vivo formation of daidzein or a daidzein derivative, and the chalcone synthase, chalcone reductase, and chalcone isomerase genes may also be transgenes. Plants transformed by this method may also preferably further comprise downstream genes, for example, isoflavone *O*-methyltransferase, isoflavone 2'-hydroxylase, isoflavone reductase, and vestitone reductase, to metabolize a formed isoflavone to biologically active isoflavonoid derivatives or conjugates. The plant can comprise isoflavone 4'-*O*-methyl-transferase to cause formation of biochanin A or a biochanin A derivative from the isoflavanone intermediate. An exemplary flavanone substrate for this transformation method is liquiritigenin and/or naringenin.

In another aspect, the present invention is a method for increasing the level of isoflavonoid compounds in naturally isoflavonoid-producing plants comprising introducing a DNA segment encoding the enzyme catalyzing the aryl migration of a flavanone to yield an isoflavonoid to form a transgenic plant, wherein the transgenic plant expresses the DNA segment under the control of a suitable constitutive or inducible promoter when the transgenic plant is exposed to conditions which permit expression. With this method, the resulting isoflavonoid can be an isoflavanone intermediate, an isoflavone, an isoflavone derivative, and an isoflavone conjugate. The DNA segment can comprise isolated genomic DNA or recombinant DNA. Preferably, the DNA segment is a CYP93C gene. An exemplary DNA segment from a soybean CYP93C gene consists essentially of the sequence from about nucleotide 36 to about nucleotide 1598 of the sequence depicted in SEQ ID NO:1. Another preferred DNA segment comprises a *Medicago truncatula* homolog of a CYP93C gene, more preferably, the sequence from about nucleotide 92 to about nucleotide 1657 of the sequence depicted in SEQ ID NO:4. An exemplary flavanone substrate for this transformation method is liquiritigenin and/or naringenin.

In another aspect, the invention is a method for synthesizing an isoflavanone intermediate or an isoflavone from a flavanone by expressing a recombinant CYP93C gene segment in a suitable bacterial, fungal, algal, or insect cell system. An exemplary gene segment consists essentially of the sequence from about nucleotide 36

to about nucleotide 1598 of the sequence depicted in SEQ ID NO:1. Another exemplary gene segment consists essentially of the sequence from about nucleotide 92 to about nucleotide 1657 of the sequence depicted in SEQ ID NO:4.

5 In another aspect, the invention is a method of reducing the levels of isoflavonoid compounds in a naturally isoflavonoid-producing plant comprising introducing and expressing an antisense or gene silencing construct that contains an intact CYP93C gene or segments thereof into the plant. An exemplary gene consists essentially of the sequence from about nucleotide 36 to about nucleotide 1598 of the sequence depicted in SEQ ID NO:1. Another exemplary gene consists essentially of
10 the sequence from about nucleotide 92 to about nucleotide 1657 of the sequence depicted in SEQ ID NO:4.

In another aspect, the invention is a naturally non-isoflavonoid-producing plant cell transformed by introducing a DNA segment encoding the enzyme catalyzing the aryl migration of a flavanone to form an isoflavanone intermediate or an isoflavone,
15 wherein the transformed plant cell expresses the DNA segment under the control of a suitable constitutive or inducible promoter when exposed to conditions which permit expression. The DNA segment can comprise isolated genomic DNA or recombinant DNA. Preferably, the DNA segment is a CYP93C gene. An exemplary DNA segment from a soybean CYP93C gene consists essentially of the sequence from about
20 nucleotide 36 to about nucleotide 1598 of the sequence depicted in SEQ ID NO:1. Another preferred DNA segment comprises a *Medicago truncatula* homolog of a CYP93C gene, more preferably, the sequence from about nucleotide 92 to about nucleotide 1657 of the sequence depicted in SEQ ID NO:4. Plants transformed by this method may also preferably express chalcone synthase, chalcone reductase, and
25 chalcone isomerase genes to cause in vivo formation of daidzein or a daidzein derivative, and the chalcone synthase, chalcone reductase, and chalcone isomerase genes may also be transgenes. Plants transformed by this method may also preferably further comprise downstream genes, for example, isoflavone *O*-methyltransferase, isoflavone 2'-hydroxylase, isoflavone reductase, and vestitone reductase, to
30 metabolize a formed isoflavanone intermediate to biologically active isoflavonoid

derivatives or conjugates. The plant can comprise isoflavone 4'-*O*-methyl-transferase to cause formation of biochanin A or a biochanin A derivative from the isoflavanone intermediate.

5 In another aspect, the invention is a naturally isoflavonoid-producing plant cell transformed by introducing a DNA segment encoding the enzyme catalyzing the aryl migration of a flavanone to yield an isoflavonoid to form a transformed plant cell, wherein the transformed plant cell expresses the DNA segment under the control of a suitable constitutive or inducible promoter when exposed to conditions which permit expression. With this method, the resulting isoflavonoid can be an isoflavanone
10 intermediate, an isoflavone, an isoflavone derivative, and an isoflavone conjugate. The DNA segment can comprise isolated genomic DNA or recombinant DNA. Preferably, the DNA segment is a CYP93C gene. An exemplary DNA segment from a soybean CYP93C gene consists essentially of the sequence from about nucleotide 36 to about nucleotide 1598 of the sequence depicted in SEQ ID NO:1. Another
15 preferred DNA segment comprises a *Medicago truncatula* homolog of a CYP93C gene, more preferably, the sequence from about nucleotide 92 to about nucleotide 1657 of the sequence depicted in SEQ ID NO:4.

In another aspect, the invention is a transgenic plant cell having reduced levels of isoflavonoid compounds, the plant cell transformed by introducing an antisense or
20 gene silencing construct that contains an intact CYP93C gene or segments thereof into the plant cell. An exemplary gene consists essentially of the sequence from about nucleotide 36 to about nucleotide 1598 of the sequence depicted in SEQ ID NO:1. Another exemplary gene consists essentially of the sequence from about nucleotide 92 to about nucleotide 1657 of the sequence depicted in SEQ ID NO:4.

25 In another aspect, the invention is an isolated gene or DNA segment comprising a portion which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the portion consists essentially of about nucleotide 36 to about nucleotide 1598 of the sequence depicted in SEQ ID NO:1. An exemplary gene is the soybean
30 gene encoding the enzyme catalyzing the aryl migration of liquiritigenin. Another

exemplary gene is the soybean gene encoding the enzyme catalyzing the aryl migration of naringenin.

In another aspect, the invention is a protein encoded by a portion of an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the portion consists essentially of about nucleotide 36 to about nucleotide 1598 of the sequence depicted in SEQ ID NO:1.

In another aspect, the invention is an isolated gene or DNA segment comprising a portion which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the portion is a *Medicago truncatula* homolog of a CYP93C gene. An exemplary gene or DNA segment consists essentially of about nucleotide 92 to about nucleotide 1657 of the sequence depicted in SEQ ID NO:4. An exemplary gene is the *Medicago truncatula* gene encoding the enzyme catalyzing the aryl migration of liquiritigenin. Another exemplary gene is the *Medicago truncatula* gene encoding the enzyme catalyzing the aryl migration of naringenin.

In another aspect, the invention is a protein encoded by a portion of an isolated gene or a DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the portion is a *Medicago truncatula* homolog of a CYP93C gene.

In yet another aspect, the invention is a food comprising edible transgenic plant material capable of being ingested for its nutritional value, wherein the transgenic plant has been transformed with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, and wherein the transgenic plant exhibits increased levels of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the isolated gene or DNA segment.

In yet another aspect, the invention is a food comprising at least one isoflavonoid, wherein the isoflavonoid is isolated from a transgenic plant transformed

with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, and wherein the transgenic plant exhibits increased levels of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the isolated gene or DNA segment.

In yet another aspect, the invention is a composition comprising at least a portion of a transgenic plant transformed with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits increased levels of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the isolated gene or DNA segment, and wherein the composition is suitable for ingestion as a food stuff, a nutritional supplement, an animal feed supplement, or a nutraceutical.

In yet another aspect, the invention is a composition comprising an isoflavonoid suitable for administration as a food stuff, a nutritional supplement, an animal feed supplement, a nutraceutical, or a pharmaceutical, wherein the isoflavonoid is isolated from at least a portion of a transgenic plant transformed with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, and wherein the transgenic plant exhibits increased levels of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the isolated gene or DNA segment.

In yet another aspect, the invention is a method of increasing the nutritional value of a plant by transforming the plant with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits increased levels of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the isolated gene or DNA segment.

In yet another aspect, the invention is a method of using a transgenic plant transformed with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the isolated gene or DNA segment, to provide a nutraceutical benefit to a human or animal administered the isoflavonoid. The isoflavonoid can be administered by ingestion of at least a portion of the plant. The isoflavonoid can also be administered by ingestion of a composition comprising an isoflavonoid isolated from the plant.

In yet another aspect, the invention is a method of using an isoflavonoid isolated from a transgenic plant transformed with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the isolated gene or DNA segment, to provide a pharmaceutical benefit to a patient administered the isoflavonoid.

In yet another aspect, the invention is a method of increasing disease resistance in a plant by transforming the plant with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the isolated gene or DNA segment.

In yet another aspect, the invention is a method of increasing nodulation efficiency of a leguminous plant by transforming the plant with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid released from the roots

when compared to the level of the isoflavonoid released from the roots of plants of the same species which do not comprise the isolated gene or DNA segment.

In yet another aspect, the invention is a transgenic leguminous plant exhibiting increased nodulation efficiency transformed with an isolated gene or DNA segment
5 which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid released from the roots when compared to the level of the isoflavonoid released from the roots of plants of the same species which do not comprise the isolated gene or DNA segment.

10 In yet another aspect, the invention is a method of increasing bacterial or fungal symbiosis in a plant by transforming the plant with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid when compared to the
15 level of the isoflavonoid in plants of the same species which do not comprise the isolated gene or DNA segment.

In yet another aspect, the invention is a transgenic plant exhibiting increased bacterial or fungal symbiosis transformed with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone
20 to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the isolated gene or DNA segment.

In yet another aspect, the invention is a transgenic plant comprising at least one
25 recombinant DNA sequence encoding a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the recombinant DNA sequence.

In yet another aspect, the invention is seed from a transgenic plant comprising at least one recombinant DNA sequence encoding a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the recombinant DNA sequence.

In yet another aspect, the invention is progeny from a transgenic plant comprising at least one recombinant DNA sequence encoding a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the recombinant DNA sequence.

In yet another aspect, the invention is progeny from seed of a transgenic plant comprising at least one recombinant DNA sequence encoding a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the recombinant DNA sequence.

In yet another aspect, the invention is use of a transgenic plant transformed with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid when compared to the level of the isoflavonoid in plants of the same species which do not comprise the isolated gene or DNA segment, for the preparation of a nutraceutical preparation for achieving a nutritional effect.

In yet another aspect, the invention is use of a transgenic plant transformed with an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein the transgenic plant exhibits an increased level of an isoflavonoid

when compared to the level of the isoflavonoid in plants of the same species which do not comprise the isolated gene or DNA segment, for the preparation of a pharmaceutical preparation for achieving a therapeutic effect.

DETAILED DESCRIPTION

5 One aspect of the present invention is an isolated gene which encodes the first step of the isoflavone synthase reaction: a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavone. Genes and corresponding cDNA of the soybean or *Medicago truncatula* CYP93 family have been isolated. The enzymes encoded by the genes of the present invention are isoflavone synthases (IFS) and can
10 catalyze the aryl migration of a flavanone to yield an isoflavone either directly or through the intermediacy of a 2-hydroxyisoflavanone. One isolated soybean gene is classified as *CYP93C1v2*.

Cytochrome P450 enzymes belong to a large superfamily of enzymes that are abundant in every living organism. The P450 nomenclature committee has
15 determined that each P450 should carry a "CYP" designation and arbitrarily divided the superfamily into families (alphabetical designation), subfamilies (numerical designation) and allelic variants ("v" plus numerical designation) based on amino acid identity of >40%, >55%, and >97%, respectively (Nelson, et al. 1993. "The P450 superfamily update on new sequences, gene mapping, accession numbers, early trivial
20 names of enzymes, and nomenclature," *DNA Cell Biol* 12:1). Thus, CYP93C1v2 is a variant of the first described P450 belonging to the third subfamily (C) of the ninety-third P450 family.

Utilizing the procedures presented herein, any plant known to produce isoflavonoids may also serve as sources of suitable DNA, or coding sequences may be
25 synthesized in vitro based on the sequences for the IFS genes of the present invention. CYP93 family members can also be obtained from other plant species by polymerase chain reaction amplification methods known to those skilled in the art, using primer sequences corresponding to regions of nucleotide conservation between CYP93 family members. Furthermore, the genes of the present invention are defined by their

catalytic activity: the aryl migration of a flavanone to yield an isoflavone. The gene sequences presented as SEQ ID NO:1 and SEQ ID NO:4 are exemplary, and it is understood that modifications to these genes which do not alter the catalytic activity of its encoded protein fall within the scope of the present invention. While a preferred IFS gene contains the entire open reading frame, portions of or the entire 5' and 3' untranslated regions as well as portions of the vector sequence can also be present. With the isolation and functional identification of these isoflavone synthase (IFS) genes that encode the first key step in isoflavone formation, the aryl migration reaction, it is now possible to introduce the isoflavonoid pathway into all plant species, including those that do not naturally possess this pathway.

Another aspect of the present invention is a genetically modified plant which has been transformed with a gene of the present invention. For example, when the *CYP93C1v2* gene is transferred into the model plant *Arabidopsis thaliana*, which does not naturally produce isoflavonoids, the isoflavone genistein accumulates as a series of glycoconjugates (Example 1). This demonstrates that the genes of the present invention can be genetically engineered into plants which do not naturally contain the isoflavonoid pathway, and the transgenic plants can then produce isoflavonoids, resulting in plants with improved disease resistance and/or value added health benefits for humans. In the present invention, unless otherwise stated, as used herein, the term "plant" or "progeny" includes plant parts, plant tissue, plant cells, plant protoplasts, plant cell tissue cultures from which plants can be regenerated, plant calli, plant clumps, explants, plant cells that are intact in plants, or parts of plants, such as embryos, pollen, ovules, flowers, capsules, stems, leaves, seeds, roots, root tips, and the like. Furthermore, the present invention includes the IFS genes expressed in various parts of the plant, e.g., in aerial portions of the plant useful for increasing disease resistance or production of health promoting isoflavonoid nutraceuticals, in seeds useful for increasing levels of isoflavones and their conjugates, or in roots useful for increasing disease resistance or production of nodulation gene inducing isoflavones.

In another aspect, the present invention is a method of improving disease resistance and a transgenic plant with increased disease resistance. By transforming a plant which does not naturally make isoflavones with an IFS gene of the present invention, disease resistance can be genetically engineered into the plant by providing
5 the necessary enzyme to convert its natural flavanones into isoflavonoids. The introduction and subsequent expression of an IFS gene of the present invention into a crop species which naturally possesses the isoflavonoid pathway results in increased levels of the isoflavonoid defense compounds.

In another aspect, the present invention is a method of increasing levels of
10 isoflavonoids that might be beneficial to the establishment of bacterial or fungal symbioses with plants and a transgenic plant with an increased capacity for symbiotic association with bacteria or fungi. Bacterial nodulation can be stimulated in transgenic leguminous plants by expression of an IFS gene of the present invention and decreased by expression of antisense constructs or constructs designed to promote
15 gene silencing that contain an intact IFS gene or segments thereof. Mycorrhizal colonization of leguminous plants can also be increased through the introduction and expression of an IFS gene of the present invention.

In yet another aspect, the present invention is a method of producing isoflavonoid compounds in plants or any other organism to be used in nutraceuticals or
20 pharmaceuticals to confer human or animal health benefits. Edible transgenic plants high in isoflavonoids can be utilized as food for humans and animals. Edible compositions high in isoflavonoids can also be made by incorporation of the transgenic plants or plant materials, or by incorporation of isoflavonoids isolated from the transgenic plants. Compositions useful for administration as a food stuff, a
25 nutritional supplement, an animal feed supplement, a nutraceutical, or a pharmaceutical can be made by incorporation of the transgenic plants or plant materials, or by incorporation of isoflavonoids isolated from the transgenic plants. The nutritional value of a plant can be increased by transforming the plant with an IFS gene of the present invention and, as a result, accumulating high amounts of
30 isoflavonoids in the plant.

The soybean IFS gene of the present invention was isolated and purified according to the detailed procedures outlined in Example 2. The DNA sequence is shown in SEQ ID NO:1 and Fig. 2, and the encoded protein sequence of the isolated soybean CYP93C clone is shown in SEQ ID NO:2 and Fig. 3. For comparison, Fig. 3 also shows the protein sequence alignment between the isolated CYP93C clone (SEQ ID NO:2) and CYP93B1 (SEQ ID NO:3), the licorice licodione synthase.

The DNA and protein sequences of the soybean CYP93C1 open reading frame were deposited in the Genbank data base under accession # AF022462. The deposition was made by Siminszky, Dewey and Corbin, and the sequence described as representing a gene induced in soybean in response to herbicide safeners. However, the function of the gene was not known and there was no understanding that it could be involved in isoflavonoid biosynthesis at the time the deposit was made (Siminszky, B., Corbin, F.T., Ward, E.R., Fleischmann, T.J. and Dewey, R.E., 1999, "Expression of a soybean cytochrome P450 monooxygenase cDNA in yeast and tobacco enhances the metabolism of phenylurea herbicides." *Proc. Natl. Acad. Sci. USA* 96: 1750-1755). The sequence of the clone characterized herein differs from CYP93C1 in three nucleotide substitutions in the open reading frame that change proline 140 to leucine, threonine 156 to isoleucine, and glutamate 295 to lysine. Thus, the soybean gene identified herein has been classified as CYP93C1v2.

The cDNA insert from CYP93C1v2 was used to probe 240,000 phage plaques from a *Medicago truncatula* root cDNA library (van Buuren, M.L., I.E. Maldonado-Mendoza, A.T. Trieu, L.A. Blaylock, and M.J. Harrison, 1999, "Novel genes induced during an arbuscular mycorrhizal (AM) symbiosis formed between *Medicago truncatula* and *Glomus versiforme*," *Mol. Plant-Microbe Interact.* 12, 171-181). Five positive plaques were purified, in vivo excised, and sequenced. A full length clone designated mtIFSE3 was completely sequenced on both strands, and shown to encode the *Medicago truncatula* homolog of soybean CYP93C1. The nucleotide sequence of mtIFSE3 is shown in SEQ ID NO:4 and Fig. 4, and the protein sequence, in SEQ ID NO:5. An alignment between the protein sequences of mtIFSE3 and CYP93C1v2 is shown in Fig. 5.

An IFS gene of the soybean or *Medicago truncatula* CYP93C subfamily or corresponding cDNA sequence, the open reading frame of which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavone, either directly or through the intermediacy of a 2-hydroxyisoflavanone, can be used to introduce the isoflavonoid pathway into any plant species that does not naturally possess this pathway. Soybean CYP93C1v2 acts on the flavanones liquiritigenin to yield daidzein, and naringenin to yield genistein. Liquiritigenin is only formed in plants that possess the enzyme chalcone reductase (CHR) (Welle, R. and Grisebach, H., 1989, "Phytoalexin synthesis in soybean cells: elicitor induction of reductase involved in biosynthesis of 6'-deoxychalcone." *Arch Biochem Biophys* 272: 97-102), and a form of chalcone isomerase that is active against 2',4,4'-trihydroxychalcone, the product of the co-action of chalcone synthase (CHS) with CHR (Dixon, R.A., Blyden, E.R., Robbins, M.P., van Tunen, A.J. and Mol, J.N.M., 1988, "Comparative biochemistry of chalcone isomerases." *Phytochemistry* 27: 2801-2808). Such genes are common in legumes, but not in most other plant families. Thus, to form daidzein in transgenic plants that do not possess the isoflavonoid pathway, it would be necessary to introduce three new genes, namely CHR, to co-act with CHS to form 2',4,4'-trihydroxychalcone, a suitable CHI to convert 2',4,4'-trihydroxychalcone to liquiritigenin, and IFS, assuming that the 2-hydroxyisoflavanone intermediate can spontaneously dehydrate in planta, a phenomenon that is demonstrated below. Without CHR present, no liquiritigenin would be formed, and IFS would only be able to act on naringenin to yield, assuming spontaneous dehydration of the 2-hydroxyisoflavanone, genistein.

The IFS genes of the present invention can be introduced into non-leguminous plants such as by standard *Agrobacterium*-based or biolistic transformation procedures (Horsch, et al., 1985, "A simple and general method for transferring genes into plants," *Science* 227:1229-1231; and Klein, et al., 1988, "Stable genetic transformation of intact *Nicotiana* cells by the particle bombardment process," *Proc Natl Acad Sci USA* 85:8502-8505). Both procedures require the construction of a plasmid vector containing a desirable transcriptional promoter driving expression of the gene of interest (in this case IFS), followed by a transcriptional terminator and a

selectable marker gene for resistance, such as to an antibiotic or a herbicide. The biolistic procedure coats metal particles with plasmid DNA containing the gene of interest and places them on a micro carrier disk. Using the biolistic apparatus, the particles are physically propelled into plant tissue. The plant tissue is then put under
5 selection (e.g., antibiotic or herbicide) followed by regeneration. The two *Agrobacterium*-based procedures are “in planta” and “ex-planta”, respectively. Both procedures require the above gene construct to be placed into a T-DNA vector, which is then transferred into *Agrobacterium tumefaciens*. The in planta procedure places the transformed *Agrobacterium* in the presence of plant material (flower or meristem) and
10 the plants are allowed to seed followed by selection (e.g., antibiotic or herbicide) during germination. The ex-planta procedure also places *Agrobacterium* in the presence of plant material (callus, cell culture, leaf disk, hypocotyl) which is placed directly under selection (e.g., antibiotic or herbicide) followed by regeneration.

Thus, the isoflavonoid pathway can be introduced into any plant species that
15 does not possess the enzyme catalyzing the IFS reaction by expressing the IFS gene in transgenic plants under the control of a suitable constitutive or inducible promoter.

**Example 1: Transformation of *Arabidopsis thaliana*
with Soybean *CYP93C1V2***

Soybean CYP93C1v2 cDNA was placed in the binary plant transformation
20 vector pCHF3, in which it is under control of the cauliflower mosaic virus 35S promoter, using standard recombinant DNA methods (Sambrook, et al. 1989. *Molecular Cloning. A Laboratory Manual*, 2nd Ed, Cold Spring Harbor Laboratory Press, New York). The gene was then transformed into plants of the crucifer, *Arabidopsis thaliana* ecotype Columbia, using *Agrobacterium tumefaciens* and a
25 standard floral infiltration procedure (Clough, S.J. and Bent, A.F., 1998, “Floral dip: a simplified method for *Agrobacterium*-mediated transformation of *Arabidopsis thaliana*”. *Plant J* 16: 735-743). Transgenic plants were selected by germinating the seedlings on kanamycin, and those surviving selection were allowed to set seed. T₂ seedlings expressing CYP93C1v2 were identified by standard DNA and RNA gel blot
30 analysis (Sambrook, et al. 1989. *Molecular cloning. A Laboratory Manual*, 2nd Ed,

Cold Spring Harbor Laboratory Press, New York), and analyzed for accumulation of genistein in leaves by HPLC analysis, according to a method developed to profile the flavonoid components of *Arabidopsis* leaves (Graham, T.L., 1998, "Flavonoid and flavonol glycoside metabolism in *Arabidopsis*". *Plant Physiol Biochem* 36: 135-144).

5 Figure 6A shows a typical HPLC trace of a leaf extract from an untransformed plant. The major components are glycosides (containing glucose and rhamnose) of the flavonols kaempferol and quercetin. Plants harboring the soybean CYP93C1v2 gene showed an additional three peaks on HPLC analysis (Fig. 6B), indicated by the arrows labeled as "1," "2" and "3." No free genistein, free 2-hydroxyisoflavanone or 2-
10 hydroxyisoflavanone conjugates were observed. However, following treatment of extracts with almond β -glucosidase (Fig 7B), one of the new peaks disappeared, and free genistein was now observed, consistent with the peak being a glucoside of genistein. LC-MS analysis confirmed the identities of the new compounds as a glucoside of genistein, glucose-rhamnose-genistein, and rhamnose-genistein (Figs. 6C
15 and 7C and 7D, insets). Therefore, expression of CYP93C1v2 in transgenic *Arabidopsis* leads to formation of genistein with no requirement for an enzyme to catalyze the dehydration of the presumed 2-hydroxyisoflavanone intermediate. *Arabidopsis* plants then modify the genistein by exactly the same chemistry they use to conjugate their endogenous flavonols, namely by conjugation to glucose and
20 rhamnose. Transgenic production of conjugates of genistein are suitable for nutraceutical applications, because genistein is also glycosylated in soybean, its natural dietary source (Graham, T.L., 1991, "Flavonoid and isoflavonoid distribution in developing soybean seedling tissues and in seed and root exudates." *Plant Physiol* 95: 594-603).

25 In addition to introducing the isoflavonoid pathway into plants that do not possess this pathway, the level of isoflavonoid compounds can be controlled in plants that do possess the pathway by manipulating the level of expression of the IFS gene. Increasing the levels of isoflavonoid compounds in leguminous plants by expression of the IFS gene of the present invention in transgenic plants under the control of a
30 suitable constitutive or inducible promoter can be accomplished by standard methods

such as *Agrobacterium*-based or biolistic transformation methods known in the art. Alternatively, the level of isoflavonoid compounds in plants can be reduced by expression of antisense constructs or constructs designed to promote gene silencing that contain an intact IFS gene, or segments thereof, in transgenic plants using methods known in the art. (Bourque, J.E., 1995, "Antisense strategies for genetic manipulations in plants," *Plant Science* 105:125-149; and Angell, S. M. and D. C. Baulcombe, 1997, "Consistent gene silencing in transgenic plants expressing a replicating potato virus X RNA," *EMBO J* 16:3675-3684). Antisense constructs for gene silencing are constructed by placing the whole or part of the cDNA in a three prime to five prime orientation behind a desirable transcriptional promoter and ahead of a transcriptional terminator in a plasmid vector. The vector may be used for biolistic transformation or the new antisense gene may be transferred to a T-DNA vector for *Agrobacterium*-based transformation. The actual mechanism of silencing by antisense constructs is unknown. Homology-dependent gene silencing or co-suppression requires the over-expression of a homologous gene; therefore, to achieve co-suppression a construct is made using a strong promoter, the gene of interest (in this case IFS) and a transcriptional terminator. The gene should be transferred to plants as described above. Gene silencing is an epigenetic phenomenon that may or may not occur with a particular gene construct. When it does occur, the inhibition of gene expression can be greater than with the antisense approach.

Isoflavones can be synthesized from flavanones, utilizing recombinant IFS expressed in any suitable bacterial, fungal, algal, or insect cell system. For example, naringenin is extracted in large amounts from grapefruits. A CYP93C1 enzyme can be used convert naringenin to 2,5,7,4'-tetrahydroxyisoflavanone, which spontaneously converts to the valuable nutraceutical genistein under weak acid conditions. Furthermore, daidzin can be synthesized from liquiritigenin utilizing recombinant CYP93C1 and an isoflavone glucosyltransferase (Köster, J. and W. Barz, 1981, "UDP-Glucose: isoflavone 7-O-glucosyltransferase from roots of chick pea (*Cicer arietinum* L.)." *Arch Biochem Biophys* 212: 98-104).

Example 2: Methodology Used to Isolate and Identify IFS cDNA Clones

In an attempt to obtain cDNA clones encoding IFS, a functional genomics approach was followed. IFS activity is present in soybean seeds, which accumulate daidzein and genistein. Furthermore, IFS activity can be induced in soybean tissues in response to infection with *Phytophthora infestans*, associated with the accumulation of the isoflavonoid phytoalexin glyceollin (Bhattacharyya, M. K. and E. W. B. Ward, 1987, "Biosynthesis and metabolism of glyceollin I in soybean hypocotyls following wounding or inoculation with *Phytophthora megasperma* f. sp. *glycinea*," *Physiol Mol Plant Path* 31: 387-405). It was also known that an enzyme catalyzing a similar reaction to IFS, namely the 2-hydroxylation of flavanone but without aryl migration, belongs to the CYP93B1 subclass of cytochrome P450s (Akashi, et al, 1998, "Identification of a cytochrome P450 cDNA encoding (2S)-flavanone 2-hydroxylase of licorice (*Glycyrrhiza echinata* L.: *Fabaceae*) which represents licodione synthase and flavone synthase II," *FEBS Letters* 431: 287-290). We therefore searched an expressed sequence tag (EST) database of partial soybean sequences obtained by mass sequencing of two cDNA libraries: a *Phytophthora*-infected hypocotyl cDNA library (48 hours after infection) and a mid to late developmental stage seed library. Nine candidate P450 sequences were identified, of which three belonged to the CYP93 family. DNA probes were made from the EST clones of the three CYP93 candidates and were used to probe an RNA blot of transcripts from alfalfa suspension cells at various times after exposure to yeast elicitor, a treatment known to induce IFS activity at the onset of isoflavonoid phytoalexin accumulation (Kessmann, et al., 1990, "Stress responses in alfalfa (*Medicago sativa* L.) III. Induction of medicarpin and cytochrome P450 enzyme activities in elicitor-treated cell suspension cultures and protoplasts," *Plant Cell Reports* 9: 38-41). One P450 probe cross-hybridized and detected alfalfa transcripts that were strongly induced by elicitation. This probe was derived from a clone with high homology to soybean CYP93C1 as described below, and the insert in the EST clone was full length. The insert was excised and then cloned into the baculovirus expression system for functional identification by heterologous expression in insect cells (Pauli, H. H. and T. M. Kutchan, 1998, "Molecular cloning and functional heterologous expression of two alleles encoding (S)-N-methylcoclaurine 3'-

hydroxylase (CYP80B1), a new methyl jasmonate-inducible cytochrome P-450-dependent mono-oxygenase of benzylisoquinoline alkaloid biosynthesis," *The Plant J* 13: 793-801).

5 The carbon monoxide difference spectrum of microsomes isolated from insect cells expressing the soybean CYP93C clone indicated the presence of expressed cytochrome P450, as seen from an absorption peak at 450 nm that was not present in similar spectra from insect microsomes originating from cells transformed with a control vector. Unlabeled liquiritigenin was then fed to the microsomes in the presence of NADPH. The substrate remained unconverted in microsomes from cells
10 harboring the control vector. However, in microsomes expressing the CYP93C clone, a new peak of RT 29.96 min was observed by high performance liquid chromatography (Fig 8A). The amount of this peak was reduced 10-fold if NADPH was omitted from the incubations (Fig. 8B). The UV spectrum of the product, obtained by diode array detection, was identical to that of authentic daidzein ($\lambda_{\max}$
15 248 nm, sh 302 nm, $\lambda_{\min}$ 222 nm). The product was collected, derivatized, and analyzed by GC-MS. The mass spectrum of the BSTFA derivative was identical to that of an authentic sample of daidzein (Fig. 9). Microsomes containing the CYP93C clone also metabolized naringenin to yield genistein, although somewhat less efficiently than the reaction with liquiritigenin (Fig. 8C). Insect cell microsomes
20 expressing a different soybean cytochrome P450 cDNA, CYP93E, did not convert liquiritigenin to daidzein when incubated in the presence of NADPH (Fig. 8D). These results indicate that the soybean CYP93C encodes IFS.

Example 3: Method of Increasing Dietary Isoflavonoid Intake

Transgenic tomato plants are produced by the introduction of *CYP93C1v2* via
25 standard *Agrobacterium*-based procedures. In a preferred embodiment, the *CYP93C1v2* coding sequence is under control of a gene promoter giving specific expression in the fruit. Progeny containing the coding region of the *CYP93C1v2* gene are selected at the seedling stage by standard polymerase chain reaction and/or DNA blot analysis known to those skilled in the art. Plants scoring positive for possession
30 of the transgene are grown to fruiting, and fruit analyzed for the presence of

isoflavones by the HPLC methods shown in Fig. 7 and Fig. 8 of the present invention. Fruit harvested from the transgenic tomato plants are ingested to increase the dietary intake of isoflavonoids.

5 It is to be understood that the above description is of preferred exemplary embodiments of the invention and is intended to be illustrative of the invention, but is not to be construed to limit the scope of the invention in any way. Modifications may be made in the structural features of the invention without departing from the scope of the invention.

10 In summary, isoflavones can now be genetically engineered to provide potential human health benefits of dietary isoflavones and to increase disease resistance in plants. Isoflavones can now be produced in transgenic plants species in which isoflavones do not naturally occur, i.e., in species other than legumes. For example, engineering constitutive production of daidzein and/or genistein or their conjugates into tomato, potato, corn, or other popular components of the human diet, 15 leads to human health benefits, such as reduced cancer risk, reduced incidence of osteoporosis, and treatment for alcoholism. Alternatively, introducing infection-inducible isoflavonoid biosynthesis into non-legumes qualitatively complements these plants' phytoalexin defenses against microbial pathogens, whereas over-expression of the isoflavonoid pathway in legumes quantitatively increases this defense response. 20 Finally, modifying the extent of production of isoflavonoids in legume roots positively impacts nodulation efficiency and therefore plant yield.

SEQUENCE LISTING

(1) GENERAL INFORMATION;

(i) APPLICANT:

- (A) NAME: The Samuel Roberts Noble Foundation, Inc.
- (B) STREET ADDRESS: 2510 Sam Noble Parkway
- (C) CITY: Ardmore
- (D) STATE/PROVINCE: Oklahoma
- (E) COUNTRY: US
- (F) POSTAL CODE/ZIP: 73401
- (G) TELEPHONE: 580-224-6207
- (H) TELEFAX: 580-224-6692

(ii) TITLE OF INVENTION: Genetic Manipulation of Isoflavonoids

(iii) NUMBER OF SEQUENCES: 5

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Kirby Eades Gale Baker
- (B) STREET: 112 Kent Street, Suite 770
- (C) CITY: Ottawa
- (D) PROVINCE: Ontario
- (E) COUNTRY: CANADA
- (F) POSTAL CODE: K1P 5P2

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #2.1

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: 2362440
- (B) FILING DATE: 2000-03-08

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: PCT/US00/05915
- (B) FILING DATE: 2000-03-08

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 60/123,267

(B) FILING DATE: 1999-03-08

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Kimberley Lachaine

(B) REFERENCE/DOCKET NUMBER: 46893-NP

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 613-237-6900

(B) TELEFAX: 613-270-0332

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 1717 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

(D) TOPOLOGY: both

(ii) MOLECULE TYPE: genomic DNA

(iii) ORIGINAL SOURCE: Glycine max

(iv) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

gagcaaagat caaacaaacc aaggacgaga acacg atg ttg ctt gaa ctt gca      53
                                Met Leu Leu Glu Leu Ala
                                1              5
ctt ggt tta ttg gtt ttg gct ctg ttt ctg cac ttg cgt ccc aca ccc      101
Leu Gly Leu Leu Val Leu Ala Leu Phe Leu His Leu Arg Pro Thr Pro
                10              15              20
act gca aaa tca aaa gca ctt cgc cat ctc cca aac cca cca agc cca      149
Thr Ala Lys Ser Lys Ala Leu Arg His Leu Pro Asn Pro Pro Ser Pro
                25              30              35
aag cct cgt ctt ccc ttc ata gga cac ctt cat ctc tta aaa gac aaa      197
Lys Pro Arg Leu Pro Phe Ile Gly His Leu His Leu Leu Lys Asp Lys
                40              45              50
ctt ctc cac tac gca ctc atc gac ctc tcc aaa aaa cat ggt ccc tta      245
Leu Leu His Tyr Ala Leu Ile Asp Leu Ser Lys Lys His Gly Pro Leu
                55              60              65              70

```

ttc tct ctc tac ttt ggc tcc atg cca acc gtt gtt gcc tcc aca cca	293
Phe Ser Leu Tyr Phe Gly Ser Met Pro Thr Val Val Ala Ser Thr Pro	
75 80 85	
gaa ttg ttc aag ctc ttc ctc caa acg cac gag gca act tcc ttc aac	341
Glu Leu Phe Lys Leu Phe Leu Gln Thr His Glu Ala Thr Ser Phe Asn	
90 95 100	
aca agg ttc caa acc tca gcc ata aga cgc ctc acc tat gat agc tca	389
Thr Arg Phe Gln Thr Ser Ala Ile Arg Arg Leu Thr Tyr Asp Ser Ser	
105 110 115	
gtg gcc atg gtt ccc ttc gga cct tac tgg aag ttc gtg agg aag ctc	437
Val Ala Met Val Pro Phe Gly Pro Tyr Trp Lys Phe Val Arg Lys Leu	
120 125 130	
atc atg aac gac ctt ctc aac gcc acc act gta aac aag ttg agg cct	485
Ile Met Asn Asp Leu Leu Asn Ala Thr Thr Val Asn Lys Leu Arg Pro	
135 140 145 150	
ttg agg acc caa cag atc cgc aag ttc ctt agg gtt atg gcc caa ggc	533
Leu Arg Thr Gln Gln Ile Arg Lys Phe Leu Arg Val Met Ala Gln Gly	
155 160 165	
gca gag gca cag aag ccc ctt gac ttg acc gag gag ctt ctg aaa tgg	581
Ala Glu Ala Gln Lys Pro Leu Asp Leu Thr Glu Glu Leu Leu Lys Trp	
170 175 180	
acc aac agc acc atc tcc atg atg atg ctc ggc gag gct gag gag atc	629
Thr Asn Ser Thr Ile Ser Met Met Met Leu Gly Glu Ala Glu Glu Ile	
185 190 195	
aga gac atc gct cgc gag gtt ctt aag atc ttt ggc gaa tac agc ctc	677
Arg Asp Ile Ala Arg Glu Val Leu Lys Ile Phe Gly Glu Tyr Ser Leu	
200 205 210	
act gac ttc atc tgg cca ttg aag cat ctc aag gtt gga aag tat gag	725
Thr Asp Phe Ile Trp Pro Leu Lys His Leu Lys Val Gly Lys Tyr Glu	
215 220 225 230	
aag agg atc gac gac atc ttg aac aag ttc gac cct gtc gtt gaa agg	773
Lys Arg Ile Asp Asp Ile Leu Asn Lys Phe Asp Pro Val Val Glu Arg	
235 240 245	
gtc atc aag aag cgc cgt gag atc gtg agg agg aga aag aac gga gag	821
Val Ile Lys Lys Arg Arg Glu Ile Val Arg Arg Arg Lys Asn Gly Glu	
250 255 260	
gtt gtt gag ggt gag gtc agc ggg gtt ttc ctt gac act ttg ctt gaa	869
Val Val Glu Gly Glu Val Ser Gly Val Phe Leu Asp Thr Leu Leu Glu	
265 270 275	

ttc gct gag gat gag acc atg gag atc aaa atc acc aag gac cac atc	917
Phe Ala Glu Asp Glu Thr Met Glu Ile Lys Ile Thr Lys Asp His Ile	
280 285 290	
aag ggt ctt gtt gtc gac ttt ttc tcg gca gga aca gac tcc aca gcg	965
Lys Gly Leu Val Val Asp Phe Phe Ser Ala Gly Thr Asp Ser Thr Ala	
295 300 305 310	
gtg gca aca gag tgg gca ttg gca gaa ctc atc aac aat cct aag gtg	1013
Val Ala Thr Glu Trp Ala Leu Ala Glu Leu Ile Asn Asn Pro Lys Val	
315 320 325	
ttg gaa aag gct cgt gag gag gtc tac agt gtt gtg gga aag gac aga	1061
Leu Glu Lys Ala Arg Glu Glu Val Tyr Ser Val Val Gly Lys Asp Arg	
330 335 340	
ctt gtg gac gaa gtt gac act caa aac ctt cct tac att aga gca atc	1109
Leu Val Asp Glu Val Asp Thr Gln Asn Leu Pro Tyr Ile Arg Ala Ile	
345 350 355	
gtg aag gag aca ttc cgc atg cac ccg cca ctc cca gtg gtc aaa aga	1157
Val Lys Glu Thr Phe Arg Met His Pro Pro Leu Pro Val Val Lys Arg	
360 365 370	
aag tgc aca gaa gag tgt gag att aat gga tat gtg atc cca gag gga	1205
Lys Cys Thr Glu Glu Cys Glu Ile Asn Gly Tyr Val Ile Pro Glu Gly	
375 380 385 390	
gca ttg att ctc ttc aat gta tgg caa gta gga aga gac ccc aaa tac	1253
Ala Leu Ile Leu Phe Asn Val Trp Gln Val Gly Arg Asp Pro Lys Tyr	
395 400 405	
tgg gac aga cca tcg gag ttc cgt cct gag agg ttc cta gag aca ggg	1301
Trp Asp Arg Pro Ser Glu Phe Arg Pro Glu Arg Phe Leu Glu Thr Gly	
410 415 420	
gct gaa ggg gaa gca ggg cct ctt gat ctt agg gga caa cat ttt caa	1349
Ala Glu Gly Glu Ala Gly Pro Leu Asp Leu Arg Gly Gln His Phe Gln	
425 430 435	
ctt ctc cca ttt ggg tct ggg agg aga atg tgc cct gga gtc aat ctg	1397
Leu Leu Pro Phe Gly Ser Gly Arg Arg Met Cys Pro Gly Val Asn Leu	
440 445 450	
gct act tcg gga atg gca aca ctt ctt gca tct ctt att cag tgc ttc	1445
Ala Thr Ser Gly Met Ala Thr Leu Leu Ala Ser Leu Ile Gln Cys Phe	
455 460 465 470	
gac ttg caa gtg ctg ggt cca caa gga cag ata ttg aag ggt ggt gac	1493
Asp Leu Gln Val Leu Gly Pro Gln Gly Gln Ile Leu Lys Gly Gly Asp	
475 480 485	

```

gcc aaa gtt agc atg gaa gag aga gcc ggc ctc act gtt cca agg gca 1541
Ala Lys Val Ser Met Glu Glu Arg Ala Gly Leu Thr Val Pro Arg Ala
      490              495              500
cat agt ctt gtc tgt gtt cca ctt gca agg atc ggc gtt gca tct aaa 1589
His Ser Leu Val Cys Val Pro Leu Ala Arg Ile Gly Val Ala Ser Lys
      505              510              515
ctc ctt tct taattaagat catcgatcatc atcatcatat gtaatatatta 1638
Leu Leu Ser
      520
ctttttgtgt gttgataatc atcatttcaa taagggtctca ttcacttact ttttatgaag 1698
tatataagcc cttccatgc 1717

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 521 amino acids

(B) TYPE: amino acid

(C) TOPOLOGY:

(ii) MOLECULE TYPE: protein

(iii) ORIGINAL SOURCE: Glycine max

(iv) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Leu Leu Glu Leu Ala Leu Gly Leu Leu Val Leu Ala Leu Phe Leu
  1              5              10              15
His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg His Leu
      20              25              30
Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly His Leu
      35              40              45
His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp Leu Ser
      50              55              60
Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met Pro Thr
      65              70              75              80
Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Thr His
      85              90              95
Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile Arg Arg
      100             105             110
Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Phe Gly Pro Tyr Trp
      115             120             125
Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala Thr Thr
      130             135             140

```

Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys Phe Leu			
145	150	155	160
Arg Val Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp Leu Thr			
	165	170	175
Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met Met Leu			
	180	185	190
Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu Lys Ile			
	195	200	205
Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys His Leu			
	210	215	220
Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn Lys Phe			
	225	230	240
Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile Val Arg			
	245	250	255
Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Val Ser Gly Val Phe			
	260	265	270
Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu Ile Lys			
	275	280	285
Ile Thr Lys Asp His Ile Lys Gly Leu Val Val Asp Phe Phe Ser Ala			
	290	295	300
Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala Glu Leu			
	305	310	320
Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Val Tyr Ser			
	325	330	335
Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln Asn Leu			
	340	345	350
Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His Pro Pro			
	355	360	365
Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile Asn Gly			
	370	375	380
Tyr Val Ile Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp Gln Val			
	385	390	400
Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg Pro Glu			
	405	410	415
Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Gly Pro Leu Asp Leu			
	420	425	430
Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Arg Met			
	435	440	445
Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu Leu Ala			
	450	455	460

Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln Gly Gln
 465 470 475 480
 Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg Ala Gly
 485 490 495
 Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu Ala Arg
 500 505 510
 Ile Gly Val Ala Ser Lys Leu Leu Ser
 515 520

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 523 amino acids

(B) TYPE: amino acid

(C) TOPOLOGY:

(ii) MOLECULE TYPE: protein

(iii) ORIGINAL SOURCE: Glycyrrhiza echinata

(iv) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Glu Pro Gln Leu Val Ala Val Ser Val Leu Val Ser Ala Leu Ile
 1 5 10 15
 Cys Tyr Phe Phe Phe Arg Pro Tyr Phe His Arg Tyr Gly Lys Asn Leu
 20 25 30
 Pro Pro Ser Pro Phe Phe Arg Leu Pro Ile Ile Gly His Met His Met
 35 40 45
 Leu Gly Pro Leu Leu His Gln Ser Phe His Asn Leu Ser His Arg Tyr
 50 55 60
 Gly Pro Leu Phe Ser Leu Asn Phe Gly Ser Val Leu Cys Val Val Ala
 65 70 75 80
 Ser Thr Pro His Phe Ala Lys Gln Leu Leu Gln Thr Asn Glu Leu Ala
 85 90 95
 Phe Asn Cys Arg Ile Glu Ser Thr Ala Val Lys Lys Leu Thr Tyr Glu
 100 105 110
 Ser Ser Leu Ala Phe Ala Pro Tyr Gly Asp Tyr Trp Arg Phe Ile Lys
 115 120 125
 Lys Leu Ser Met Asn Glu Leu Leu Gly Ser Arg Ser Ile Asn Asn Phe
 130 135 140
 Gln His Leu Arg Ala Gln Glu Thr His Gln Leu Leu Arg Leu Leu Ser
 145 150 155 160
 Asn Arg Ala Arg Ala Phe Glu Ala Val Asn Ile Thr Glu Glu Leu Leu
 165 170 175

Lys Leu Thr Asn Asn Val Ile Ser Ile Met Met Val Gly Glu Ala Glu
 180 185 190
 Glu Ala Arg Asp Val Val Arg Asp Val Thr Glu Ile Phe Gly Glu Phe
 195 200 205
 Asn Val Ser Asp Phe Ile Trp Leu Phe Lys Lys Met Asp Leu Gln Gly
 210 215 220
 Phe Gly Lys Arg Ile Glu Asp Leu Phe Gln Arg Phe Asp Thr Leu Val
 225 230 235 240
 Glu Arg Ile Ile Ser Lys Arg Glu Gln Thr Arg Lys Asp Arg Arg Arg
 245 250 255
 Asn Gly Lys Lys Gly Glu Gln Gly Ser Gly Asp Gly Ile Arg Asp Phe
 260 265 270
 Leu Asp Ile Leu Leu Asp Cys Thr Glu Asp Glu Asn Ser Glu Ile Lys
 275 280 285
 Ile Gln Arg Val His Ile Lys Ala Leu Ile Met Asp Phe Phe Thr Ala
 290 295 300
 Gly Thr Asp Thr Thr Ala Ile Ser Thr Glu Trp Ala Leu Val Glu Leu
 305 310 315 320
 Val Lys Lys Pro Ser Val Leu Gln Lys Val Arg Glu Glu Ile Asp Asn
 325 330 335
 Val Val Gly Lys Asp Arg Leu Val Glu Glu Ser Asp Cys Pro Asn Leu
 340 345 350
 Pro Tyr Leu Gln Ala Ile Leu Lys Glu Thr Phe Arg Leu His Pro Pro
 355 360 365
 Val Pro Met Val Thr Arg Arg Cys Val Ala Glu Cys Thr Val Glu Asn
 370 375 380
 Tyr Val Ile Pro Glu Asp Ser Leu Leu Phe Val Asn Val Trp Ser Ile
 385 390 395 400
 Gly Arg Asn Pro Lys Phe Trp Asp Asn Pro Leu Glu Phe Arg Pro Glu
 405 410 415
 Arg Phe Leu Lys Leu Glu Gly Asp Ser Ser Gly Val Val Asp Val Arg
 420 425 430
 Gly Ser His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Arg Met Cys
 435 440 445
 Pro Gly Val Ser Leu Ala Met Gln Glu Val Pro Ala Leu Leu Gly Ala
 450 455 460
 Ile Ile Gln Cys Phe Asp Phe His Val Val Gly Pro Lys Gly Glu Ile
 465 470 475 480
 Leu Lys Gly Asp Asp Ile Val Ile Asn Val Asp Glu Arg Pro Gly Leu
 485 490 495

Thr Ala Pro Arg Ala His Asn Leu Val Cys Val Pro Val Asp Arg Thr
 500 505 510
 Ser Gly Gly Gly Pro Leu Lys Ile Ile Glu Cys
 515 520

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 1811 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

(D) TOPOLOGY: both

(ii) MOLECULE TYPE: genomic DNA

(iii) ORIGINAL SOURCE: Medicago truncatula

(iv) SEQUENCE DESCRIPTION: SEQ ID NO:4:

caacacctaa gagtaactaa taagaacttt ctttctactt cttagtatac ttaacaactt 60
 aagtaaatat actacaaaga agctatacac c atg ttg gtg gaa ctt gca gtt 112
 Met Leu Val Glu Leu Ala Val
 1 5
 act cta ttg ctc att gct ctc ttc tta cac ttg cgt cca aca cct act 160
 Thr Leu Leu Leu Ile Ala Leu Phe Leu His Leu Arg Pro Thr Pro Thr
 10 15 20
 gca aaa tca aag gct ctt cgc cac ctt cca aat cca cca agc cct aaa 208
 Ala Lys Ser Lys Ala Leu Arg His Leu Pro Asn Pro Pro Ser Pro Lys
 25 30 35
 cca cgt ctt cca ttc ata ggt cat ctt cac ctt ttg gat aac cca ctt 256
 Pro Arg Leu Pro Phe Ile Gly His Leu His Leu Leu Asp Asn Pro Leu
 40 45 50 55
 ctt cac cac act ctt atc aag tta gga aag cgt tat ggc cct ttg tac 304
 Leu His His Thr Leu Ile Lys Leu Gly Lys Arg Tyr Gly Pro Leu Tyr
 60 65 70
 act ctt tac ttt ggt tcc atg cct acc gtt gtt gca tcc act cct gac 352
 Thr Leu Tyr Phe Gly Ser Met Pro Thr Val Val Ala Ser Thr Pro Asp
 75 80 85
 ttg ttt aaa ctt ttc ctt caa acc cat gaa gct act tcc ttt aac aca 400
 Leu Phe Lys Leu Phe Leu Gln Thr His Glu Ala Thr Ser Phe Asn Thr
 90 95 100
 aga ttc caa acc tct gct att agt cgt ctt acc tat gac aac tct gtt 448
 Arg Phe Gln Thr Ser Ala Ile Ser Arg Leu Thr Tyr Asp Asn Ser Val
 105 110 115

gct atg gtt cca ttt gca cct tat tgg aag ttt att aga aag ctt atc	496
Ala Met Val Pro Phe Ala Pro Tyr Trp Lys Phe Ile Arg Lys Leu Ile	
120 125 130 135	
atg aac gac ttg ctc aac gcc acc act gtt aac aaa ttg agg cca ttg	544
Met Asn Asp Leu Leu Asn Ala Thr Thr Val Asn Lys Leu Arg Pro Leu	
140 145 150	
agg agc cga gaa atc ctt aag gtt ctt aag gtc atg gct aat agt gct	592
Arg Ser Arg Glu Ile Leu Lys Val Leu Lys Val Met Ala Asn Ser Ala	
155 160 165	
gaa act caa cag cca ctt gat gtc act gag gag ctt ctc aag tgg aca	640
Glu Thr Gln Gln Pro Leu Asp Val Thr Glu Glu Leu Leu Lys Trp Thr	
170 175 180	
aac agc aca atc tct acc atg atg ttg ggt gag gcc gaa gag gtt aga	688
Asn Ser Thr Ile Ser Thr Met Met Leu Gly Glu Ala Glu Glu Val Arg	
185 190 195	
gat att gct cgt gat gtt ctt aag atc ttt gga gaa tat agt gtt aca	736
Asp Ile Ala Arg Asp Val Leu Lys Ile Phe Gly Glu Tyr Ser Val Thr	
200 205 210 215	
aac ttt att tgg cct ttg aac aag ttt aag ttt gga aac tat gat aag	784
Asn Phe Ile Trp Pro Leu Asn Lys Phe Lys Phe Gly Asn Tyr Asp Lys	
220 225 230	
aga act gag gag att ttc aat aag tat gat cct atc att gaa aag gtt	832
Arg Thr Glu Glu Ile Phe Asn Lys Tyr Asp Pro Ile Ile Glu Lys Val	
235 240 245	
atc aag aaa cga caa gag att gtg aac aaa aga aaa aat gga gaa atc	880
Ile Lys Lys Arg Gln Glu Ile Val Asn Lys Arg Lys Asn Gly Glu Ile	
250 255 260	
gta gaa ggc gag cag aat gtt gtt ttt ctt gac act ttg ctt gaa ttt	928
Val Glu Gly Glu Gln Asn Val Val Phe Leu Asp Thr Leu Leu Glu Phe	
265 270 275	
gca caa gat gag acc atg gag atc aaa att aca aag gaa caa atc aag	976
Ala Gln Asp Glu Thr Met Glu Ile Lys Ile Thr Lys Glu Gln Ile Lys	
280 285 290 295	
ggg ctt gtt gtg gat ttt ttc tct gca gga aca gac tcc acc gcc gtg	1024
Gly Leu Val Val Asp Phe Phe Ser Ala Gly Thr Asp Ser Thr Ala Val	
300 305 310	
tct aca gaa tgg act tta tca gag ctc atc aat aat cct aga gtg ttg	1072
Ser Thr Glu Trp Thr Leu Ser Glu Leu Ile Asn Asn Pro Arg Val Leu	
315 320 325	

```

aag aaa gct cga gag gag att gac tct gtt gtg gga aaa gat aga ctg 1120
Lys Lys Ala Arg Glu Glu Ile Asp Ser Val Val Gly Lys Asp Arg Leu
      330              335              340
gtt gat gaa tca gat gtt cag aat ctt cct tac att aaa gcc atc gta 1168
Val Asp Glu Ser Asp Val Gln Asn Leu Pro Tyr Ile Lys Ala Ile Val
      345              350              355
aaa gaa gca ttt cgc ttg cac cca cca cta cct gta gtc aaa aga aaa 1216
Lys Glu Ala Phe Arg Leu His Pro Pro Leu Pro Val Val Lys Arg Lys
360              365              370              375
tgt aca caa gaa tgt gag atc gac ggg tat gtg gtt cca gaa gga gca 1264
Cys Thr Gln Glu Cys Glu Ile Asp Gly Tyr Val Val Pro Glu Gly Ala
      380              385              390
cta ata ctt ttc aat gtc tgg gca gtg gga aga gac cca aaa tat tgg 1312
Leu Ile Leu Phe Asn Val Trp Ala Val Gly Arg Asp Pro Lys Tyr Trp
      395              400              405
gta aag cca ttg gaa ttt cgt cca gag agg ttc ata gaa aat gtt ggt 1360
Val Lys Pro Leu Glu Phe Arg Pro Glu Arg Phe Ile Glu Asn Val Gly
      410              415              420
gaa ggt gaa gca gct tca att gat ctt agg ggt caa cat ttc aca ctt 1408
Glu Gly Glu Ala Ala Ser Ile Asp Leu Arg Gly Gln His Phe Thr Leu
      425              430              435
cta cca ttt ggg tct gga aga agg atg tgt cct gga gtc aat ttg gct 1456
Leu Pro Phe Gly Ser Gly Arg Arg Met Cys Pro Gly Val Asn Leu Ala
440              445              450              455
act gca gga atg gcc aca atg att gca tct att atc caa tgc ttc gat 1504
Thr Ala Gly Met Ala Thr Met Ile Ala Ser Ile Ile Gln Cys Phe Asp
      460              465              470
ctc caa gta cct ggt caa cat gga gaa ata ttg aat ggt gat tat gct 1552
Leu Gln Val Pro Gly Gln His Gly Glu Ile Leu Asn Gly Asp Tyr Ala
      475              480              485
aag gtt agc atg gaa gag aga cct ggt ctc aca gtt cca agg gca cat 1600
Lys Val Ser Met Glu Glu Arg Pro Gly Leu Thr Val Pro Arg Ala His
      490              495              500
aat ctc atg tgt gtt cct ctt gca aga gct ggt gtc gca gat aaa ctt 1648
Asn Leu Met Cys Val Pro Leu Ala Arg Ala Gly Val Ala Asp Lys Leu
      505              510              515
ctt tcc tcc taaaatatct tgagaggatg aatcaccaac atatagcctc 1697
Leu Ser Ser
520

```

tcttttggtac tacaaaatta tgatgtaatt ttcttatttt ttctgtcaca aaggaagtgt 1757
 tgtaacttgt aattgcatac aaaatctata aattttatca tcctattcat tatt 1811

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 522 amino acids

(B) TYPE: amino acids

(C) TOPOLOGY:

(ii) MOLECULE TYPE: protein

(iii) ORIGINAL SOURCE: Medicago truncatula

(vi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met	Leu	Val	Glu	Leu	Ala	Val	Thr	Leu	Leu	Leu	Ile	Ala	Leu	Phe	Leu	1	5	10	15
His	Leu	Arg	Pro	Thr	Pro	Thr	Ala	Lys	Ser	Lys	Ala	Leu	Arg	His	Leu	20	25	30	
Pro	Asn	Pro	Pro	Ser	Pro	Lys	Pro	Arg	Leu	Pro	Phe	Ile	Gly	His	Leu	35	40	45	
His	Leu	Leu	Asp	Asn	Pro	Leu	Leu	His	His	Thr	Leu	Ile	Lys	Leu	Gly	50	55	60	
Lys	Arg	Tyr	Gly	Pro	Leu	Tyr	Thr	Leu	Tyr	Phe	Gly	Ser	Met	Pro	Thr	65	70	75	80
Val	Val	Ala	Ser	Thr	Pro	Asp	Leu	Phe	Lys	Leu	Phe	Leu	Gln	Thr	His	85	90	95	
Glu	Ala	Thr	Ser	Phe	Asn	Thr	Arg	Phe	Gln	Thr	Ser	Ala	Ile	Ser	Arg	100	105	110	
Leu	Thr	Tyr	Asp	Asn	Ser	Val	Ala	Met	Val	Pro	Phe	Ala	Pro	Tyr	Trp	115	120	125	
Lys	Phe	Ile	Arg	Lys	Leu	Ile	Met	Asn	Asp	Leu	Leu	Asn	Ala	Thr	Thr	130	135	140	
Val	Asn	Lys	Leu	Arg	Pro	Leu	Arg	Ser	Arg	Glu	Ile	Leu	Lys	Val	Leu	145	150	155	160
Lys	Val	Met	Ala	Asn	Ser	Ala	Glu	Thr	Gln	Gln	Pro	Leu	Asp	Val	Thr	165	170	175	
Glu	Glu	Leu	Leu	Lys	Trp	Thr	Asn	Ser	Thr	Ile	Ser	Thr	Met	Met	Leu	180	185	190	
Gly	Glu	Ala	Glu	Glu	Val	Arg	Asp	Ile	Ala	Arg	Asp	Val	Leu	Lys	Ile	195	200	205	
Phe	Gly	Glu	Tyr	Ser	Val	Thr	Asn	Phe	Ile	Trp	Pro	Leu	Asn	Lys	Phe	210	215	220	

Lys Phe Gly Asn Tyr Asp Lys Arg Thr Glu Glu Ile Phe Asn Lys Tyr			
225	230	235	240
Asp Pro Ile Ile Glu Lys Val Ile Lys Lys Arg Gln Glu Ile Val Asn			
	245	250	255
Lys Arg Lys Asn Gly Glu Ile Val Glu Gly Glu Gln Asn Val Val Phe			
	260	265	270
Leu Asp Thr Leu Leu Glu Phe Ala Gln Asp Glu Thr Met Glu Ile Lys			
	275	280	285
Ile Thr Lys Glu Gln Ile Lys Gly Leu Val Val Asp Phe Phe Ser Ala			
	290	295	300
Gly Thr Asp Ser Thr Ala Val Ser Thr Glu Trp Thr Leu Ser Glu Leu			
305	310	315	320
Ile Asn Asn Pro Arg Val Leu Lys Lys Ala Arg Glu Glu Ile Asp Ser			
	325	330	335
Val Val Gly Lys Asp Arg Leu Val Asp Glu Ser Asp Val Gln Asn Leu			
	340	345	350
Pro Tyr Ile Lys Ala Ile Val Lys Glu Ala Phe Arg Leu His Pro Pro			
	355	360	365
Leu Pro Val Val Lys Arg Lys Cys Thr Gln Glu Cys Glu Ile Asp Gly			
	370	375	380
Tyr Val Val Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp Ala Val			
385	390	395	400
Gly Arg Asp Pro Lys Tyr Trp Val Lys Pro Leu Glu Phe Arg Pro Glu			
	405	410	415
Arg Phe Ile Glu Asn Val Gly Glu Gly Glu Ala Ala Ser Ile Asp Leu			
	420	425	430
Arg Gly Gln His Phe Thr Leu Leu Pro Phe Gly Ser Gly Arg Arg Met			
	435	440	445
Cys Pro Gly Val Asn Leu Ala Thr Ala Gly Met Ala Thr Met Ile Ala			
	450	455	460
Ser Ile Ile Gln Cys Phe Asp Leu Gln Val Pro Gly Gln His Gly Glu			
465	470	475	480
Ile Leu Asn Gly Asp Tyr Ala Lys Val Ser Met Glu Glu Arg Pro Gly			
	485	490	495
Leu Thr Val Pro Arg Ala His Asn Leu Met Cys Val Pro Leu Ala Arg			
	500	505	510
Ala Gly Val Ala Asp Lys Leu Leu Ser Ser			
	515	520	

CLAIMS:

1. A method for introducing into a naturally non-isoflavonoid-producing plant species an enzyme catalyzing the aryl migration of a flavanone to form an isoflavanone intermediate or an isoflavone, said enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, the method comprising:
5 introducing a DNA segment encoding said enzyme into said plant to form a transgenic plant, wherein said transgenic plant expresses said DNA segment under the control of a suitable constitutive or inducible promoter when said transgenic plant is
10 exposed to conditions which permit expression.
2. The method of Claim 1, wherein chalcone synthase, chalcone reductase, and chalcone isomerase genes are also expressed in said plant to cause in vivo formation of daidzein or a daidzein derivative.
15
3. The method of Claim 2, wherein said plant is further transformed to comprise said chalcone synthase, chalcone reductase, and chalcone isomerase genes.
4. The method of Claim 1 or 2, wherein said plant further comprises
20 downstream genes to metabolize said formed isoflavanone intermediate or isoflavone to biologically active isoflavonoid derivatives or conjugates.
5. The method of Claim 4, wherein said downstream gene is selected from the group consisting of isoflavone *O*-methyltransferase, isoflavone 2'-hydroxylase,
25 isoflavone reductase, and vestitone reductase.
6. The method of Claim 5, wherein said plant comprises downstream gene 4'-*O*-methyltransferase to form biochanin A or a biochanin A derivative.
7. A method for increasing the level of isoflavonoid compounds in naturally
30 isoflavonoid-producing plants comprising:

introducing a DNA segment encoding an enzyme catalyzing the aryl migration of a flavanone to yield an isoflavonoid to form a transgenic plant, said enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, wherein said transgenic plant expresses said DNA segment under the control of a suitable constitutive or inducible promoter when said transgenic plant is exposed to conditions which permit expression.

8. The method of Claim 7, wherein said isoflavonoid is selected from the group consisting of an isoflavanone intermediate, an isoflavone, an isoflavone derivative, and an isoflavone conjugate.

9. The method of Claim 1, 7 or 8, wherein said DNA segment comprises isolated genomic DNA.

10. The method of Claim 1, 7 or 8, wherein said DNA segment comprises recombinant cDNA.

11. The method of Claims 1-10, wherein said flavanone is liquiritigenin.

12. The method of Claims 1-10, wherein said flavanone is naringenin.

13. A method for synthesizing an isoflavanone intermediate or an isoflavone from a flavanone by expressing a recombinant CYP93C gene segment encoding an enzyme having an amino acid sequence as set forth in SEQ ID NO:2, in a suitable bacterial, fungal, algal, or insect cell system.

14. A method of reducing the levels of isoflavonoid compounds in a naturally isoflavonoid-producing plant comprising introducing and expressing an antisense or gene silencing construct that contains a CYP93C gene encoding an enzyme having an amino acid sequence as set forth in SEQ ID NO:2, into said plant.

15. The method of Claim 1, 13 or 14, wherein said gene consists of the sequence from nucleotide 36 to nucleotide 1598 of the sequence depicted in SEQ ID NO:1.

5 16. A naturally non-isoflavonoid producing plant cell transformed by introducing a DNA segment encoding an enzyme catalyzing the aryl migration of a flavanone to form an isoflavanone intermediate or an isoflavone, said enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, wherein said transgenic plant cell expresses said DNA segment under the control of a suitable
10 constitutive or inducible promoter when exposed to conditions which permit expression.

17. The plant cell of Claim 16, wherein chalcone synthase, chalcone reductase, and chalcone isomerase genes are also expressed in said plant to cause in
15 vivo formation of daidzein or a daidzein derivative.

18. The plant cell of Claim 17, wherein said plant cell is further transformed to comprise said chalcone synthase, chalcone reductase, and chalcone isomerase genes.
20

19. The plant cell of Claim 16 or 17, wherein said plant cell further comprises downstream genes to metabolize said formed isoflavanone intermediate or isoflavone to biologically active isoflavonoid derivatives or conjugates.

25 20. The plant cell of Claim 19, wherein said downstream gene is selected from the group consisting of isoflavone *O*-methyltransferase, isoflavone 2'-hydroxylase, isoflavone reductase, and vestitone reductase.

21. The plant cell of Claim 20, wherein said plant cell comprises downstream
30 gene 4'-*O*-methyltransferase to form biochanin A or a biochanin A derivative.

22. A naturally isoflavonoid-producing plant cell transformed by introducing a DNA segment encoding an enzyme catalyzing the aryl migration of a flavanone to yield an isoflavonoid to form a transformed plant cell, said enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, wherein said transformed plant cell
5 expresses said DNA segment under the control of a suitable constitutive or inducible promoter when exposed to conditions which permit expression.

23. The plant cell of Claim 22, wherein said isoflavonoid is selected from the group consisting of an isoflavanone intermediate, an isoflavone, an isoflavone
10 derivative, and an isoflavone conjugate.

24. The plant cell of Claim 16, 22 or 23, wherein said DNA segment comprises isolated genomic DNA.

15 25. The plant cell of Claim 16, 22 or 23, wherein said DNA segment comprises recombinant cDNA.

26. A transgenic plant cell having reduced levels of isoflavonoid compounds, said plant cell transformed by introducing an antisense or gene silencing construct that
20 contains a CYP93C gene encoding an enzyme having an amino acid sequence as set forth in SEQ ID NO:2, into said plant cell.

27. The plant cell of Claim 26, wherein said gene consists of the sequence from nucleotide 36 to nucleotide 1598 of the sequence depicted in SEQ ID NO:1.
25

28. An isolated gene or DNA segment comprising a portion which encodes a cytochrome P450 of the CYP93 family that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein said portion consists of nucleotide 36 to nucleotide 1598 of the sequence depicted in SEQ ID
30 NO:1.

29. The gene or DNA segment of Claim 28, wherein said gene is the soybean gene encoding the enzyme catalyzing the aryl migration of liquiritigenin.

30. The gene or DNA segment of Claim 28, wherein said gene is the soybean
5 gene encoding the enzyme catalyzing the aryl migration of naringenin.

31. A protein encoded by a portion of an isolated gene or DNA segment which encodes a cytochrome P450 that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, wherein said portion consists
10 of nucleotide 36 to nucleotide 1598 of the sequence depicted in SEQ ID NO:1.

32. A transgenic plant cell transformed with an isolated gene or DNA segment which encodes a cytochrome P450 enzyme that can catalyze the aryl migration of a flavanone to yield an isoflavanone intermediate or an isoflavone, said
15 enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, wherein said transgenic plant cell exhibits increased levels of an isoflavonoid when compared to the level of said isoflavonoid in plant cells of the same species which do not comprise said isolated gene or DNA segment.

20 33. A food capable of being ingested for its nutritional value, wherein said food comprises plant cells according to claim 32.

34. A method of preparing a food comprising at least one isoflavonoid comprising:
25 transforming a plant according to the method of claim 1 or 7, wherein said transgenic plant exhibits increased levels of an isoflavonoid when compared to the level of said isoflavonoid in plants of the same species which do not comprise said DNA segment, isolating said isoflavonoid and incorporating into said food.

35. A composition comprising a transgenic plant cell according to claim 32, wherein said composition is suitable for ingestion as a food stuff, a nutritional supplement, an animal feed supplement, or a nutraceutical.

5 36. A method of preparing a composition comprising an isoflavonoid suitable for administration as a food stuff, a nutritional supplement, an animal feed supplement, a nutraceutical, or a pharmaceutical, comprising:
transforming a plant according to the method of Claim 1 or 7, wherein said transgenic plant exhibits increased levels of an isoflavonoid when compared to the level of said
10 isoflavonoid in plants of the same species which do not comprise said DNA segment, isolating said isoflavonoid and incorporating into said compositions.

37. Use of a transgenic plant cell according to Claim 32 to provide a nutraceutical benefit to a human or animal administered said isoflavonoid.

15

38. Use of Claim 37, wherein said isoflavonoid is in a form for administration by ingestion of said plant cell.

39. Use of Claim 37, wherein said isoflavonoid is in a form for administration
20 by ingestion of a composition comprising an isoflavonoid isolated from said plant cell.

40. Use of a transgenic plant cell according to Claim 32 in the manufacture of a medicament to provide a nutraceutical benefit to a human or animal administered said isoflavonoid.

25

41. Use of Claim 40, wherein said isoflavonoid is in a form for administration by ingestion of said plant cell.

42. Use of Claim 40, wherein said isoflavonoid is in a form for administration
30 by ingestion of a composition comprising an isoflavonoid isolated from said plant cell.

43. A method for making a pharmaceutical preparation, comprising:
transforming a plant according to the method of Claim 1 or 7, wherein said transgenic
plant exhibits increased levels of an isoflavonoid when compared to the level of said
isoflavonoid in plants of the same species which do not comprise said DNA segment,
5 isolating said isoflavonoid and formulating said isoflavonoid to form a pharmaceutical
preparation.

44. A method of transforming a plant with an isolated gene or DNA segment
which encodes a cytochrome P450 enzyme that can catalyze the aryl migration of a
10 flavanone to yield an isoflavanone intermediate or an isoflavone, said enzyme
comprising an amino acid sequence as set forth in SEQ ID NO:2, wherein said
transgenic plant exhibits increased levels of an isoflavonoid when compared to the
level of said isoflavonoid in plants of the same species which do not comprise said
isolated gene or DNA segment.

15

45. A method of Claim 44, wherein the nutritional value of said plant is
increased.

46. A method of Claim 44, wherein the disease resistance in said plant is
20 increased.

47. A method of Claim 44, wherein bacterial or fungal symbiosis in said plant
is increased.

25 48. A method of Claim 44, wherein said plant is a leguminous plant

49. A method of Claim 48, wherein the nodulation efficiency of said plant is
increased.

50. A leguminous transgenic plant cell derived from a transgenic plant exhibiting increased nodulation efficiency, wherein said transgenic plant cell is transformed according to the method of Claim 44.

5 51. A transgenic plant cell of Claim 32 exhibiting an increased level of bacterial or fungal symbiosis.

52. A transgenic plant cell comprising at least one recombinant DNA sequence encoding a cytochrome P450 enzyme that can catalyze the aryl migration of
10 a flavanone to yield an isoflavanone intermediate or an isoflavone, said enzyme comprising an amino acid sequence as set forth in SEQ ID NO:2, wherein said transgenic plant cell exhibits an increased level of an isoflavonoid when compared to the level of said isoflavonoid in plant cells of the same species which do not comprise said recombinant DNA sequence.

15

53. Use of a transgenic plant cell according to Claim 32 for the preparation of a nutraceutical preparation for achieving a nutritional effect.

54. Use of a transgenic plant cell according to Claim 32 for the preparation of
20 a pharmaceutical preparation for achieving a therapeutic effect.

1/15




Fig. 1

2/15

```
1  GAGCAAAGAT CAAACAAACC AAGGACGAGA ACACGATGTT GCTTGAAC TT
51  GCACTTGGTT TATTGGTTTT GGCTCTGTTT CTGCACTTGC GTCCCACACC
101 CACTGCAAAA TCAAAAGCAC TTCGCCATCT CCCAAACCCA CCAAGCCCCA
151 AGCCTCGTCT TCCCTTCATA GGACACCTTC ATCTCTTAAA AGACAAACTT
201 CTCCACTACG CACTCATCGA CCTCTCCAAA AAACATGGTC CCTTATTCTC
251 TCTCTACTTT GGCTCCATGC CAACCGTTGT TGCCTCCACA CCAGAATTGT
301 TCAAGCTCTT CCTCCAAACG CACGAGGCAA CTTCTTCAA CACAAGGTTC
351 CAAACCTCAG CCATAAGACG CCTCACCTAT GATAGCTCAG TGGCCATGGT
401 TCCCTTCGGA CCTTACTGGA AGTTCGTGAG GAAGCTCATC ATGAACGACC
451 TTCTCAACGC CACCACTGTA AACAAGTTGA GGCCTTTGAG GACCCAACAG
501 ATCCGCAAGT TCCTTAGGGT TATGGCCCAA GCGCGAGAGG CACAGAAGCC
551 CCTTGACTTG ACCGAGGAGC TTCTGAAATG GACCAACAGC ACCATCTCCA
601 TGATGATGCT CGGCGAGGCT GAGGAGATCA GAGACATCGC TCGCGAGGTT
651 CTTAAGATCT TTGGCGAATA CAGCCTCACT GACTTCATCT GGCCATTGAA
701 GCATCTCAAG GTTGGAAAGT ATGAGAAGAG GATCGACGAC ATCTTGAACA
751 AGTTCGACCC TGTCGTTGAA AGGGTCATCA AGAAGCGCCG TGAGATCGTG
801 AGGAGGAGAA AGAACGGAGA GGTGTGTTGAG GGTGAGGTCA GCGGGGTTTT
851 CCTTGACACT TTGCTTGAAT TCGCTGAGGA TGAGACCATG GAGATCAAAA
901 TCACCAAGGA CCACATCAAG GGTCTTGTTG TCGACTTTTT CTCGGCAGGA
951 ACAGACTCCA CAGCGGTGGC AACAGAGTGG GCATTGGCAG AACTCATCAA
1001 CAATCCTAAG GTGTTGGAAA AGGCTCGTGA GGAGGTCTAC AGTGTTGTGG
1051 GAAAGGACAG ACTTGTGGAC GAAGTTGACA CTCAAAACCT TCCTTACATT
1101 AGAGCAATCG TGAAGGAGAC ATTCCGCATG CACCCGCCAC TCCCAGTGGT
1151 CAAAAGAAAG TGCACAGAAG AGTGTGAGAT TAATGGATAT GTGATCCCAG
1201 AGGGAGCATT GATTCTCTTC AATGTATGGC AAGTAGGAAG AGACCCCAA
1251 TACTGGGACA GACCATCGGA GTTCCGTCCT GAGAGGTTCC TAGAGACAGG
1301 GGCTGAAGGG GAAGCAGGGC CTCTTGATCT TAGGGGACAA CATTTTCAAC
1351 TTCTCCCATT TGGGTCTGGG AGGAGAATGT GCCCTGGAGT CAATCTGGCT
1401 ACTTCGGGAA TGGCAACACT TCTTGCATCT CTTATTCAGT GCTTCGACTT
1451 GCAAGTGCTG GGTCCACAAG GACAGATATT GAAGGGTGGT GACGCCAAAG
1501 TTAGCATGGA AGAGAGAGCC GGCCTCACTG TTCCAAGGGC ACATAGTCTT
1551 GTCTGTGTTC CACTTGCAAG GATCGGCGTT GCATCTAAAC TCCTTTCTTA
1601 ATTAAGATCA TCGTCATCAT CATCATATGT AATATTTACT TTTTGTGTGT
1651 TGATAATCAT CATTTCAATA AGGTCTCATT CATCTACTTT TTATGAAGTA
1701 TATAAGCCCT TCCATGC
```

Fig. 2

[illegible]

Fig. 3

4/15

```
1    CAACACCTAA GAGTAACTAA TAAGAACTTT CTTTCTACTT CTTAGTATAC
51   TTAACAACTT AAGTAAATAT ACTACAAAGA AGCTATACAC CATGTTGGTG
101  GAACTTGCAG TTACTCTATT GCTCATTGCT CTCTTCTTAC ACTTGCGTCC
151  AACACCTACT GCAAAATCAA AGGCTCTTCG CCACCTTCCA AATCCACCAA
201  GCCCTAAACC ACGTCTTCCA TTCATAGGTC ATCTTCACCT TTTGGATAAC
251  CCACTTCTTC ACCACACTCT TATCAAGTTA GGAAAGCGTT ATGGCCCTTT
301  GTACACTCTT TACTTTGGTT CCATGCCTAC CGTTGTTGCA TCCACTCCTG
351  ACTTGTTTAA ACTTTTCCTT CAAACCCATG AAGCTACTTC CTTTAACACA
401  AGATTCCAAA CCTCTGCTAT TAGTCGTCTT ACCTATGACA ACTCTGTTGC
451  TATGGTTCCA TTTGCACCTT ATTGGAAGTT TATTAGAAAG CTTATCATGA
501  ACGACTTGCT CAACGCCACC ACTGTTAACA AATTGAGGCC ATTGAGGAGC
551  CGAGAAATCC TTAAGGTTCT TAAGGTCATG GCTAATAGTG CTGAAACTCA
601  ACAGCCACTT GATGTCACTG AGGAGCTTCT CAAGTGGACA AACAGCACAA
651  TCTCTACCAT GATGTTGGGT GAGGCCGAAG AGGTTAGAGA TATTGCTCGT
701  GATGTTCTTA AGATCTTTGG AGAATATAGT GTTACAAACT TTATTTGGCC
751  TTTGAACAAG TTTAAGTTTG GAAACTATGA TAAGAGAACT GAGGAGATTT
801  TCAATAAGTA TGATCCTATC ATTGAAAAGG TTATCAAGAA ACGACAAGAG
851  ATTGTGAACA AAAGAAAAAA TGGAGAAATC GTAGAAGGCG AGCAGAATGT
901  TGTTTTTCTT GACACTTTGC TTGAATTTGC ACAAGATGAG ACCATGGAGA
951  TCAAAATTAC AAAGGAACAA ATCAAGGGTC TTGTTGTGGA TTTTTTCTCT
1001 GCAGGAACAG ACTCCACCGC CGTGTCTACA GAATGGACTT TATCAGAGCT
1051 CATCAATAAT CCTAGAGTGT TGAAGAAAGC TCGAGAGGAG ATTGACTCTG
1101 TTGTGGGAAA AGATAGACTG GTTGATGAAT CAGATGTTCA GAATCTTCCT
1151 TACATTAAAG CCATCGTAAA AGAAGCATT TCGCTTGCACC CACCACTACC
1201 TGTAGTCAAA AGAAAATGTA CACAAGAATG TGAGATCGAC GGGTATGTGG
1251 TTCCAGAAGG AGCACTAATA CTTTTCAATG TCTGGGCAGT GGAAGAGAC
1301 CCAAAATATT GGGTAAAGCC ATTGGAATTT CGTCCAGAGA GGTTCATAGA
1351 AAATGTTGGT GAAGGTGAAG CAGCTTCAAT TGATCTTAGG GGTCAACATT
1401 TCACACTTCT ACCATTTGGG TCTGGAAGAA GGATGTGTCC TGGAGTCAAT
1451 TTGGCTACTG CAGGAATGGC CACAATGATT GCATCTATTA TCCAATGCTT
1501 CGATCTCCAA GTACCTGGTC AACATGGAGA AATATTGAAT GGTGATTATG
1551 CTAAGGTTAG CATGGAAGAG AGACCTGGTC TCACAGTTCC AAGGGCACAT
1601 AATCTCATGT GTGTTCTCTT TGCAAGAGCT GGTGTCGCAG ATAAACTTCT
1651 TTCCTCCTAA AATATCTTGA GAGGATGAAT CACCAACATA TAGCCTCTCT
1701 TTGGTACTAC AAAATTATGA TGTAATTTTC TTATTTTTTC TGTCACAAAG
1751 GAAGTGTTGT AACTTGTAAT TGCATACAAA ATCTATAAAT TTTATCATCC
1801 TATTCATTAT T
```

Fig. 4

[illegible]

Fig. 5

6/15




Fig. 6A




Fig. 6B




Fig. 6C

9/15




Fig. 7A

10/15




Fig. 7B




Fig. 7C




Fig. 7D




Fig. 8A




Fig. 8B

14/15




Fig. 8C




Fig. 8D

Fig. 9A






Fig. 9B





R=H; liquiritigenin

R=OH; naringenin

2-hydroxyisoflavanone

R=H; daidzein

R=OH; genistein